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 216 
1) Introduction 217 
 218 
Purpose  219 
The last decade has substantially broadened treatment options for patients with thoracic aortic pathology 220 
involving the aortic arch. Traditionally, treatment of aortic arch pathology was a domain of open cardiac surgery. 221 
The advent of combined vascular and endovascular procedures opened a new field thereby enabling treatment in 222 
previously operated and in less fit patients. As a subsequent technological leap, branched arch stent-grafts 223 
became available and are currently gaining acceptance in the community. Also, open surgery has substantially 224 
improved and the increased use of right subclavian artery cannulation and selective antegrade cerebral perfusion 225 
(SACP) at warmer lower body circulatory arrest times together with improved monitoring of organ function has 226 
substantially contributed to excellent results in these still major operations. Still, neurological complications remain 227 
a major concern of all procedures addressing aortic arch pathology irrespective if open or endo. The reduction to 228 
a minimum will be one of the major tasks of the future. 229 
 230 
Cross linking between cardiac and vascular surgery has amplified knowledge and interestingly enough, although 231 
dividing cardiac and vascular surgery into separate units was popular for a time, in many institutions they are 232 
being merged coming together again to create aortic centers, a trend which should be interpreted as a plea to 233 
work together without creating borders between specialties. 234 
 235 
Our hope is that in the future, treatment portfolios will be designed by a single group of people working together to 236 
understand the natural course of the disease where physicians are doing the right things when it comes to 237 
treatment and the entire aortic team follows an anticipative strategy to remain ahead of the disease process. 238 
 239 
 240 
The purpose of this combined effort of the European Association for Cardio-thoracic Surgery (EACTS) and the 241 
European Society for Vascular Surgery (ESVS) was to develop an expert consensus document covering all 242 
aspects of aortic arch disease and to provide the community with a pragmatic guide to understand the natural 243 
history of the various disease processes, to aid in indicating treatment and to provide support in choosing the right 244 
treatment modality in the right patient at the right point in time. Finally, this document aims at harmonizing 245 
terminology in acute and chronic proximal thoracic aortic pathology. 246 
 247 
 248 
249 
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 250 
Classes of recommendation – Table 1 251 
 252 
 253 
The recommendation grade indicates the strength of a recommendation. Definitions of the classes of 254 
recommendation are shown in Table 1. 255 
 256 
 257 
258 
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 259 
Levels of evidence 260 
 261 
 262 
263 
. 264 
 265 
 266 
 267 
268 
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 269 
Terminology  270 
 271 
The WC (Writing Committee) refers to and recommends the use of the definition of attachment zones as provided 272 
by “Reporting standards for thoracic endovascular aortic repair” which are also known as “Ishimaru-zones” in the 273 
aortic arch (1) (Figure 1). 274 
 275 
Regarding anatomical characteristics of the aortic arch, we refer to the classification of type I, type II and type III 276 
aortic arch configuration (2). There are three types of aortic arch and they are based on the relationship of the 277 
innominate artery to the aortic arch (3) Type I aortic arch is characterized by origin of all three great vessels in the 278 
same horizontal plane as the outer curvature of the aortic arch. In Type II aortic arch, the innominate artery 279 
originates between the horizontal planes of the outer and inner curvatures of the aortic arch. In type III aortic arch, 280 
the innominate artery originates below the horizontal plane of the inner curvature of the aortic arch (Figure 2). 281 
 282 
Regarding the use of descriptive terms of specific arch configurations such as gothic arch, steep arch angulation 283 
and aortic arch radius, no least common denominator could be identified to add a meaningful definition. 284 
Therefore, the use of these terms to describe a specific morphology remains subjective. 285 
 286 
Categorization of tears in aortic dissection- The WC suggests that the terms “multiple entries and reentries” be 287 
removed from clinical use and replaced by the wording “most proximal tear”, “communications between lumina” 288 
and “most distal tear” in addition to the term “primary entry tear”. This proposed wording should help create a 289 
better understanding of the pathophysiology as well as help standardize communication between physicians 290 
describing the pathology.  291 
 292 
Phases of acute aortic dissection- The WC suggests  to use the term “acute” for any dissection between the 293 
onset of symptoms and 14 days, “subacute” between 15 days and 90 days and “chronic” thereafter. 294 
 295 
Type A, type B and non-A-non-B aortic dissection- The WC refers to the original proposal from Stanford 296 
defining type A aortic dissection as any dissection involving the ascending aorta but refers to type B aortic 297 
dissection when only the descending thoracic aorta (DTA) is involved. An arch involvement either by the most 298 
proximal tear or by retrograde extension is referred to as non-A-non-B aortic dissection. 299 
 300 
Definition of complications in acute aortic dissection- The WC uses the wording of the ESVS clinical practice 301 
guidelines on the management of descending thoracic aorta diseases defining complicated type B aortic 302 
dissection as “the presence of rapid aortic expansion, aortic rupture and/ or hypotension/ shock, visceral, renal or 303 
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limb malperfusion, paraplegia/ paraparesis (spinal malperfusion), peri-aortic hematoma, Recurrent or refractory 304 
pain and refractory hypertension despite adequate medical therapy (4). 305 
 306 
The WC also applies this wording for complications in acute type A as well as acute non-A-non-B aortic dissection 307 
adding pericardial tamponade, acute aortic valve regurgitation, coronary and cerebral malperfusion to the one 308 
with either type A or non-A-non-B aortic dissection (5). 309 
 310 
Aortic arch replacement in various extent- When refering to aortic arch treatment, qualitative and semi-311 
quantitative statements should be avoided. Given the rising number of patients receiving open and endovascular 312 
therapy, it seems reasonable to refer to the treatment based classification using the terminology "zones 0-4" when 313 
describing surgery on the aortic arch. Again, "distal arch aneurysm" covers a wide range of anatomical variations 314 
and replacing the arch using a FET with an anastomosis proximal to the left carotid artery and selective re-315 
implantation using separate grafts is not adequately covered in the current definitions.  316 
 317 
One notable exception is the term "hemi-arch" which has been widely used for decades even if it also covers a 318 
wide range of surgical strategies from just replacing the ascending aorta and performing an open distal 319 
anastomosis to resecting the entire concavity of the arch down to the proximal DTA. 320 
 321 
For the purpose of this paper, total arch replacement is defined as replacing the entire aortic arch- or excluding it 322 
from circulation as it is the case when using the frozen elephant trunk (FET) technique- from the offspring of the 323 
innominate artery (IA) to a point beyond the offspring of the left subclavian artery (LSA). Reimplantation or 324 
revascularization of the supra-aortic branches can be performed in many ways and the method used is not part of 325 
the definition of total arch replacement. To facilitate communication and to harmonize the standards of reporting, 326 
defining total arch replacement as replacing (or excluding from circulation) aortic zones 0 to 2 (or beyond) seems 327 
reasonable. All other procedures on the arch should be named partial arch replacement. 328 
 329 
 330 
Residual dissection after type A repair- The chronic dissected state of aortic segments distal to the proximal 331 
repair is defined as “residual dissection after type A repair”.  332 
 333 
Chimneys, snorkels, periscopes- The WC refers to chimneys, snorkels and periscopes using the term ”parallel 334 
grafts”. 335 
 336 
 337 
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Organization 338 
 339 
Aortic team definition-The WC advocates that an aortic team should be closely involved from diagnosis to 340 
treatment and finally follow-up being led by cardiac and  vascular surgery in collaboration with anesthesiology, 341 
cardiology, radiology and genetics. A major advantage of surgery as the leading specialty is that surgeons do 342 
have the knowledge of linking radiographic findings to tissue quality which is a major component when opting for 343 
open or endovascular treatment. 344 
 345 
 346 
Additionally, centralization of care of aortic arch pathologies in large centers is recommended because this is the 347 
only way to effectively understand the natural course of the disease, provide the entire range of treatment options 348 
under one umbrella and treat potential complications of each individual therapy (6).  A streamlined emergent care 349 
pathway (24/7 availability without diversion), adequate transportation and transfer capabilities as well as rapid 350 
activation of the multidisciplinary team must be available.  351 
 352 
There is growing evidence, that there is clear correlation between numbers and outcome also in aortic medicine 353 
(7–12). With regard to imaging, it is clear that the ability to obtain a hybrid-room setting is limited in many 354 
hospitals. However, few trade-offs should be made as adequate intraoperative imaging forms the basis of reliable 355 
delivery of quality. 356 
 357 
Finally, a structured surveillance of all patients either before they reach the criteria for treatment or after treatment 358 
is strongly emphasized. One reason is quality control, another one is the potential to develop aortic pathology in 359 
non-treated upstream or downstream aortic segments.  360 
 361 
RECOMMENDATION 1 Decision making for the treatment of aortic arch pathologies by an aortic team is 362 
recommended. Class I Level C 363 
 364 
RECOMMENDATION 2 Centralization of care for aortic arch pathologies is recommended. Class I Level C 365 
 366 
RECOMMENDATION 3 Treatment of elective aortic arch pathology is recommended to be performed in 367 
specialized centers providing open and endovascular cardiac and vascular surgery on site only. Class I Level C 368 
 369 
RECOMMENDATION 4 Continuing follow-up of patients with aortic arch pathologies before and after treatment in 370 
a dedicated outpatient clinic is recommended. Class I Level C 371 
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RECOMMENDATION 5 A hybrid-room with a fixed imaging system is recommended for thoracic endovascular 372 
aortic repair involving the aortic arch. Class I Level C 373 
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 374 
2) Natural course of the disease and underlying pathologies 375 
 376 
 377 
The vast majority of aortic arch pathologies are based on either aneurysm formation or dissection. While 378 
dissection on the basis of previous aneurysm formation is rare, it is the main driver for accelerated growth during 379 
follow-up. Isolated aneurysm of the aortic arch is rare and most arch aneurysm that ultimately lead to surgical 380 
intervention are caused by aneurysms or dissections of either the ascending or the DTA which at some point 381 
extend into the arch or by penetrating aortic ulcers (PAU). 382 
 383 
Natural course of the disease 384 
 385 
Population based studies have shown that 60% of thoracic aortic aneurysms (TAA) occur in the root or the 386 
ascending aorta, 40% in the DTA and 10% include the aortic arch with some extending into more than one 387 
thoracic aortic segment (13). There is no controlled trial that specifically looked at the natural history of aortic arch 388 
disease. Several papers discussing the fate of the aortic arch do so by almost exclusively citing data that was 389 
derived from either observations on the ascending or the DTA. Moreover, contemporary observational studies and 390 
registries are heavily biased by the fact that many patients with aneurysm diameters exceeding the threshold for 391 
surgery recommended by the current guidelines do in fact undergo surgery (14). Therefore, there is a tendency 392 
towards facing dissection in patients with smaller diameters that had not yet reached the threshold for surgery. 393 
Conversely, some patients present with large aneurysms that by far exceed the current recommendations for 394 
surgery but have not yet dissected. Most papers dealing with aortic diameters and risk for dissection base their 395 
conclusions on post-dissection diameters. Due to the formation of intra- and peri-aortic hematoma, measuring the 396 
post-dissection diameter is not reliable. A study looking at patients with acute type A dissection that for some 397 
reason previously underwent imaging of the aorta has shown that aortic diameter increases by about 30% at the 398 
time of dissection (15). This clearly indicates that diameter at the time of presentation itself is not the sole 399 
predictor of the risk of dissection.  400 
 401 
The 2010 American Heart Association (AHA) (2) and 2014 European Society for Cardiology (ESC) (16) guidelines 402 
refer to various publications that focused on interventions in arch aneurysms or dissections, especially regarding 403 
hybrid procedures but the 2014 ESC guidelines do not cite a single paper on the natural history of arch aneurysm 404 
and the 2010 AHA guidelines refer only to the 1997 paper from the Yale cohort (17). Data from the Yale aortic 405 
database has demonstrated an average annual growth rate of 1mm for ascending aortic aneurysms and 2.9mm 406 
for descending aortic aneurysms. Nevertheless, growth rates vary according to the underlying disease and the 407 
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absolute size of the aneurysm. Larger aneurysms tend to grow faster. It is important to realize that 95% of 408 
patients with TAA are asymptomatic until the first event. Calculating the risk for dissection or rupture is difficult but 409 
a large study including 721 patients with TAA demonstrated an annual risk for dissection or rupture of 6.9% in 410 
patients with an aneurysm diameter greater than 60mm. Five-year survival in patients with TAA not undergoing 411 
intervention was only 54% (18,19). 412 
 413 
There are only few reports that focus specifically on the aortic arch. In a small study including 45 patients 414 
over a 14-year period with a mean follow-up of 37 months, average annual growth rate was 2.5mm per 415 
year but varied widely between 0 and 16mm. During the study period, 22% of patients suffered from 416 
rupture. The authors calculated that aneurysms with an annual growth rate of >5.5 mm per year have a 417 
67% likelihood of rupture compared with 8.3% in patients with a growth rate of <5.5 mm per year. 418 
Furthermore, in their study, aneurysm size >6.5 cm and hyperlipidemia correlated with more rapid 419 
expansion. In a multivariate analysis, growth rate was the sole independent risk factor for aneurysm 420 
rupture (OR 1.43; 95% confidence interval, 1.06-1.92; p=0.018) (20). Despite the current evidence is low, 421 
there seems to be no justification to conduct a prospective randomized trial comparing natural history to 422 
treatment.  423 
 424 
It has been shown that 21% of patients with TAA have a relative with an already known aneurysm and that 425 
patients with familial occurrence of TAA grow faster than those with sporadic forms (2.1mm per years vs. 1.6mm 426 
per year; ascending and DTA combined) (21). This is an important aspect of thoracic aortic disease and rapid 427 
progress is currently made in identifying genetic mutations causing TAA. Over the past decade, the medical 428 
community has slowly accepted the idea that patients presenting with aortic aneurysm and/or dissection are part 429 
of a wide spectrum of genetically mediated diseases that present in syndromic as well as non-syndromic forms. 430 
Marfan syndrome (MFS) has long been the only seriously considered differential diagnosis in terms of a heritable 431 
disorder of connective tissue in patients with aortic aneurysm. It has been shown that aneurysm formation in MFS 432 
is driven by excessive transforming growth factor-β (TGF-β), a ubiquitous cytokine in most mammalian cells and 433 
involved in cellular proliferation and differentiation. Loeys and Dietz identified a subset of patients sharing certain 434 
features such as a bifid uvula, hypertelorism and marked tortuosity of the vessels that had not been typically 435 
associated with MFS. The group identified mutations in the gene encoding for the TGF-β receptors 1 and 2 as the 436 
causative mutation (22,23). Identifying Loeys-Dietz syndrome (LDS) as a separate entity was important as 437 
patients with LDS suffered from acute aortic dissection at aortic diameters that had not been considered a cut-off 438 
to proceed to surgery in MFS patients. Meanwhile several different mutations in patients within the spectrum of 439 
LDS have been identified. Preliminary data suggests significant differences in the risk of acute dissection in these 440 
patients. Data from the Johns Hopkins group showed that a significant number of LDS patients had to undergo 441 
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interventions on the aortic arch after elective root replacement, something that has been rarely seen in Marfan 442 
patients. 443 
With the advent of high-throughput sequencing techniques, more and more causative mutations in non-syndromic 444 
forms of type A aortic dissection have been identified. It has been shown that 11% to 19% of patients without 445 
(known) genetic defect have first degree relative with type A aortic dissection. Identifying the causative mutation in 446 
patients presenting with type A aortic dissection has a direct impact on the indication for surgery, the extent of 447 
surgery, and the prognosis of the patient, as well as his relatives. 448 
 449 
Underlying pathologies- Aortic arch dissection 450 
 451 
According to the Stanford classification of aortic dissection, a dissection is considered to be a type A dissection if 452 
the ascending aorta is involved, regardless of the location of the primary entry tear. According to this definition, a 453 
dissection in the aortic arch is generally considered a type B dissection. But as 90% of the type B dissections 454 
occur distal to the LSA, the majority of data on type B dissection does not apply to aortic arch dissection (4). 455 
Nevertheless, the notion of "non-A-non-B" dissections needs to be established (Figure 3).  456 
 457 
Some studies have implicated anatomical variants as predisposing factors for dissections with entries in 458 
the aortic arch. In a study including 157 patients (24) that underwent surgery for acute type A aortic 459 
dissection, 14% of patients had either a common origin of the IA and the left common carotid artery 460 
(LCCA) or an origin of the LCCA from the IA and the rate of arch entries in this group was significantly 461 
higher compared to patients without this pattern (59% vs. 13%, p<0.001). Furthermore, the presence of 462 
this arch pattern was associated with a higher rate of post-operative neurological injury (OR 4.9; 95% CI, 463 
1.635-14.734; p=0.005). 464 
 465 
Type A aortic dissection 466 
 467 
The fate of the aortic arch in patients with type A aortic dissection is strongly correlated with the extent of the 468 
initial surgery. It has been clearly shown that not replacing the entire ascending aorta results in a high rate of re-469 
operations. Therefore, performing at least a primary entry  tear-oriented hemi-arch replacement is recommended. 470 
 471 
The additional burden of replacing the entire aortic arch as an adjunct to elective or emergent proximal repair is 472 
not very well defined and makes comparison with patients undergoing secondary total arch replacement difficult. 473 
Most papers reporting on outcomes after surgery for type A dissection or those dealing with re-intervention after 474 
proximal repair do not discuss arch related morbidity and mortality separately (25,26). The major risk factor for the 475 
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need of re-intervention on the aortic arch and distal aorta after repaired type A dissection is a patent false lumen. 476 
Furthermore, pseudoaneurysm or dehiscence at the level of the distal anastomosis has been described as a 477 
frequent cause for re-operation. Therefore, several groups began to advocate total arch replacement and 478 
implantation of a frozen elephant trunk in addition to proximal repair in type A dissection.  479 
 480 
Interestingly, Asian groups tend to favour a more aggressive approach and mostly recommend total arch 481 
replacement during initial surgery for type A dissection. It has been discussed whether this is also due to a more 482 
favorable anatomy in the Asian population and a more pronounced atherosclerotic burden in western countries 483 
which increases the risk for stroke during total arch replacement. In 2009, a Japanese group published one of the 484 
very few reports comparing hemi-arch replacement with an open distal anastomosis to total arch replacement 485 
(TAR) with implantation of a frozen elephant trunk (FET) (27). In 120 patients presenting with acute type A 486 
dissection, mortality was only 4% with no new cerebral events and a survival of 95% at 5 years in the FET group 487 
compared to 69% in the hemi-arch group.  488 
 489 
A Chinese-American collaboration focusing specifically on patients with type A dissection and an entry tear in the 490 
arch analyzed 104 patients who underwent FET and total arch replacement and compared them with 728 patients 491 
undergoing surgery for type A dissection with entry tears elsewhere. Operative mortality was 8.6% with a 2.9% 492 
paraplegia rate. Stroke rate was surprisingly low with 1.9%. In this series, survival and freedom form late adverse 493 
events was 89% and 85% at 8 years, respectively, after a mean follow-up of 5.6±2.6 years. Compared to other 494 
series, the time from onset of symptoms to surgery was quite long with 4.7±3.5 days. Furthermore, computed 495 
tomography (CT) results after a mean of 4.6±2.9 years postoperatively were only available in 65 patients, but 496 
showed complete false lumen obliteration in 63 patients. The authors concluded that type A dissection with entry 497 
in the arch can be treated safely by FET and total arch replacement and provides durable results (28). 498 
Unfortunately, a true comparison with patients undergoing less extensive surgery was not performed. 499 
 500 
Data from patients with MFS have shown that the extent of arch surgery during the initial intervention did not 501 
influence the need for thoraco-abdominal repair during follow-up. These data suggest that it is the dissection itself 502 
that drives the need for re-operations in these patients and that the aortic arch is only one of many segments that 503 
have to be repaired over the years (29). In a large series of MFS patients, it was shown that there was no 504 
significant difference regarding the rate of re-operation in patients with persisting dissection in the DTA after TAR 505 
compared to those without (30). The rate for re-interventions was 50% in both groups at 10 years. Nevertheless, 506 
the rate of re-operation was higher in patients with a dissection in the aortic arch where only the ascending aorta 507 
was replaced compared to those patients without a dissected arch. Therefore, in the rare cases where the 508 
dissection is confined to the aortic arch, complete exclusion of the dissection may reduce the need for re-509 
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interventions and should be attempted. The principal importance of closing the primary entry tear during the index 510 
procedure and the differences in the natural history of the disease if the primary entry tear has been effectively 511 
closed or not have been previously described (31)   512 
 513 
 514 
Type B dissection 515 
 516 
The International Registry of Acute Aortic Dissection (IRAD) investigators compared patients with and without 517 
retrograde extension of type B dissection (32). Retrograde extension into the aortic arch occurred in 16.5% of 518 
patients. There were no differences in the rate of patients presenting with complicated type B dissection. In this 519 
registry, there were no differences regarding choice of treatment by the participating centers. Patients with and 520 
without arch involvement received best medical treatment only in 53.7% vs. 56.5% (p=0.68), endovascular 521 
treatment in 32.8% vs. 31.1% (p=0.78), open operation in 11.9% vs. 9.5% (p=0.54), or hybrid approach in 1.5% 522 
vs. 3.0% (p=0.70), respectively. Furthermore, there was no difference in in-hospital mortality in patients with 523 
(10.7%) or without (10.4%) retrograde arch extension (p=0.96). Five-year survival was similar with 78.3% and 524 
77.8%, respectively (p=0.27). Unfortunately, this study did not look at those patients that not only had an arch 525 
involvement but also had their primary entry tear in the arch.  526 
 527 
A few years ago, it was proposed that patients with an entry at the inner curvature of the distal aortic arch have a 528 
higher risk to suffer from complicated type B dissection compared to those with an entry on the outer curvature 529 
(33,34). At that time it was speculated that the LSA may represent a natural barrier for progress of the dissection 530 
into the aortic arch. In this series, the incidence of primary complicated type B aortic dissection was 3 times higher 531 
in patients with an entry in the lesser curvature compared to those with an entry in the outer curvature (61% vs. 532 
21%, p = 0.003). Interestingly, a Japanese study with a total of 224 patients with type B dissection found that in 533 
multivariate analysis an entry at the outer curvature of the distal aortic arch was associated with a higher need of 534 
late open aortic surgery, aortic interventions and aortic events after a mean follow-up of 6.0±4.1 years (35). 535 
However, it has to be stated, that there are several clinical scenarios where the location of the primary entry tear 536 
remains either unclear or a matter of discussion, e.g. in combination with IMH. This might be owed to the quality 537 
of imaging or simply to a masked disease process. Serial adequate imaging may unmask the exact location of the 538 
primary entry tear within the first days after the acute event as can TEE help in elucidating the exact location (36).  539 
 540 
 541 
 542 
 543 
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 544 
Non-A-non-B aortic dissection – type B dissection involving aortic arch 545 
 546 
Both Stanford and DeBakey classifications do not address the clinical scenario when the aortic arch is dissected, 547 
but not the ascending aorta (37). In the ESC 2014 aortic guidelines the comments on Stanford classification 548 
regarding arch dissection in patients with non-dissected ascending aorta is missing (16). The 2010 AHA 549 
guidelines recommends to categorize patients with descending aortic dissection and entry within the arch as 550 
proximal type B dissection (2). Distal type B dissection refers to descending aortic dissection and entry distal to 551 
the LSA (2). The evolution of the term Non-A-non-B aortic dissection can be more seen as a kind of evolution of 552 
understanding of the pathophysiological process having been initially described in 1994 (38). In a recent study 553 
including 43 patients with descending aortic dissection and dissection components in the aortic arch, authors 554 
found 21 patients with entry in the DTA and 22 patients with entry within the aortic arch (39). The incidence of 555 
non-A non-B dissection was 11% among all patients with acute aortic dissection. Non-A non-B dissection patients 556 
presented with a common origin of the IA and LCCA in 28% and an arch origin left vertebral artery in 16%. The 557 
overwhelming majority of patients underwent aortic repair. Emergency aortic repair due to malperfusion or aortic 558 
rupture was necessary in 29% descending-entry and 36% arch-entry type patients. Another 43% descending-559 
entry and 36% arch-entry patients required aortic repair within 2 weeks after dissection onset due to rapid aortic 560 
growth, aortic rupture, new organ malperfusion or persisting pain. All patients, except for 1, required repair for 561 
aneurysm at follow-up. Overall in-hospital mortality in acute non-A non-B dissection patients was 9%. The highest 562 
in-hospital mortality of 37% was observed in arch-entry patients who underwent emergency surgery.  563 
 564 
Clinical presentation, treatment and outcome in non-A non-B dissection patients are different from those 565 
commonly reported for patients with acute type B dissection. The involvement of arch in dissection process of the 566 
DTA seems to have an important impact on clinical course and outcome, therefore it is reasonable not to 567 
categorize these patients as type B, but as non-A non-B aortic dissection. 568 
 569 
Aortic Intramural Hematoma 570 
 571 
The ESC guidelines define aortic intramural hematoma (IMH) as a circular or crescent-shaped thickening >5mm 572 
of the aortic wall with absence of a dissecting membrane, intimal disruption or false lumen flow (16). The ESVS 573 
guidelines define intramural hematoma as the presence of blood within the aortic wall without intimal 574 
disruption or an identifiable entry point on imaging (4). While current guidelines see IMH as a separate entity, 575 
distinguishing between IMH and dissection may not always be possible in clinical practice. There is certainly a 576 
time-dependent variable with regard to diagnosis as patients frequently present with new intimal lesions 24 to 48 577 
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hours after the initial imaging studies were performed. The current definition of IMH may be challenged as more 578 
sophisticated imaging methods will be able to identify more primary entry tears and therefore identify more IMH as 579 
a precursor of acute aortic dissection. 580 
 581 
Some of the predictive factors for disease progression that have been proposed for patients with IMH without 582 
associated ulcer or intimal erosion include involvement of the ascending aorta, aortic diameter >50 mm in initial 583 
imaging as well as persistent pain. Predictors of disease progression in patients with IMH and an associated 584 
aortic ulcer or intimal erosion include increase of associated pleural effusion, recurrent pain, ulcer located in the 585 
ascending aorta or arch with initial maximum ulcer diameter >20mm or more and initial maximum ulcer depth 586 
>10mm (40,41). In a German multicenter study, 60% of IMH patients revealed evidence of significant progression 587 
and 20% developed overt dissection within 30 days of hospital admission (42). 588 
 589 
Data are particularly scarce on IMH in the aortic arch. In a 2012 publication on IMH from the IRAD investigators, 590 
the authors analyzed 178 patients. 42% of whom presented with type A and 58% with type B IMH. In 24 (13%) of 591 
these the most proximal extent was in the aortic arch. Separate analysis of these patients showed that 16 were 592 
medically managed, 4 underwent surgery, 2 received endovascular treatment, and 2 had hybrid interventions. 593 
There were 3 deaths (12.5%) in the population and the authors concluded that this group had a slightly higher 594 
mortality and increased need for interventions than patients presenting with type B IMH (43). 595 
 596 
 597 
Penetrating Aortic Ulcer  598 
 599 
The current ESC guidelines on aortic disease define PAU as an ulceration of an aortic atherosclerotic plaque 600 
penetrating through the internal elastic lamina into the media. It is thought that PAU represents 2 to 7% of all 601 
patients with acute aortic syndromes. While there are no controlled studies regarding the natural history of PAU in 602 
different settings, reports have shown that PAU can result in the development of true aortic aneurysm, IMH or 603 
aortic dissection. Patients presenting with PAU frequently have a high atherosclerotic burden. Risk factors for 604 
PAU include advanced age, male gender, tobacco smoking, hypertension, coronary artery disease, chronic 605 
obstructive pulmonary disease, and presence of abdominal aneurysm. In a study from the Mayo Clinic including 606 
105 patients, ulcerations were located in the DTA in 94 patients, in 11 patients in the aortic arch and 10% 607 
presented with PAUs in multiple locations. Interestingly, the rate of PAUs located in the arch was significantly 608 
higher in the group of patients that was asymptomatic compared to those that were symptomatic (20% vs. 5%, 609 
p=0.03) (44).  610 
 611 
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 612 
 613 
This data is in line with a large series of 388 patients from the Philadelphia group presenting with PAU where 614 
6.8% of patients had PAUs located in the aortic arch. The authors report a higher number of open repairs in this 615 
patient group but there is no data regarding specific outcome parameters (45). Indications for intervention 616 
according to the current guidelines include persistent or recurrent pain, contained rupture, rapid growth, periaortic 617 
hematoma and pleural effusion. It is thought that in asymptomatic PAU a diameter >20mm and a neck >10mm 618 
have a higher risk of progression and early intervention should be evaluated. 619 
 620 
 621 
Recommendation for open and endovascular interventions based on aortic diameter 622 
 623 
Given the paucity of data on the natural history as well as the varying results of open surgery, there are few 624 
recommendations regarding the optimal timing of surgery solely based on the diameter of the arch. The current 625 
guidelines recommend surgery in isolated arch aneurysms at a diameter of 55mm. Both, the AHA and the ESC 626 
guidelines acknowledge the fact that the indication for surgery in arch aneurysm is strongly influenced by the 627 
overall vascular situation and especially the diameter of the adjacent ascending and descending aortic segments. 628 
In the majority of patients, this will determine the threshold for intervention. 629 
 630 
RECOMMENDATION 6 Treatment of isolated aortic arch aneurysms should be considered at a diameter of 631 
55mm. Class IIA Level B (2)632 
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 633 
3) Imaging and diagnostic work-up  634 
 635 
Computed Tomography Angiography 636 
CT is the most commonly used imaging modality to assess the aorta and has many advantages over other 637 
imaging modalities. Currently, it remains the modality of first choice (46). It is able to quickly acquire high spatial 638 
resolution three-dimensional (3D) images of the aorta and surrounding structures and enable diagnosis and aid in 639 
planning treatment.  640 
 641 
The acquisition should start cranially to the aortic arch and include the supra-aortic branches- ideally the circle of 642 
Willis, and extend caudally to the level of the femoral heads. A scan prior to contrast administration (“native”) is 643 
performed in some institutions for some questions, e.g. to rule out IMH. A total of 50 to 120 ml of contrast medium 644 
(CM) is generally needed (0.5 to 0.7 g of iodine per kilogram of body weight) (47,48). At the CT console a region 645 
of interest (ROI) marker is placed in the thoracic aorta. When the contrast enhancement reaches a certain density 646 
threshold (e.g. 120 Hounsfield Units, HU) within the chosen ROI the start of the scan is delayed for a few seconds 647 
(depending on the scanners’ speed) to perform data acquisition at the correct position in the ideal moment of the 648 
arterial phase. If needed for evaluation of e.g. organ perfusion, a second scan in the venous phase may be 649 
acquired after a delay of 60- 90 seconds upon arrival of contrast. 650 
 651 
CT data can be acquired with reference to the electrocardiogram (ECG) signal to provide images of each phase 652 
of the cardiac cycle, in order to minimize the artifacts from cardiac pulsation and aortic wall motion, which requires 653 
a low pitch down to 0.2, i.e. a slow-moving table. There are two techniques to obtain an ECG- gated CTA, pro- or 654 
retrospectively (49). Artifacts from an incompliant patient, bowel or breathing motion are not compensated. To 655 
describe cardiac or vessel motion during an R-R’-interval a maximum of twenty 3D data sets of the entire cardiac 656 
cycle can be gained using retrospective triggering. This allows reconstruction of max. 20 3D CTA. This dynamic 657 
CTA provides information on aortic movement and dynamic changes in aortic perfusion. However, radiation dose 658 
of retrospectively triggered or gated CTA is much higher in comparison to conventional CTA (49,50). The use of 659 
dual source technology and the high pitch that can be achieved with this technique (up to 3.4), may overcome the 660 
need for ECG-triggering and thus reduce radiation dose, without loss of diagnostic accuracy (51).   661 
 662 
Post-processing of axial CT data is possible using multiplanar reformation (MPR), maximal intensity projection 663 
(MIP) and volume rendering technique (VRT) (49,52). MPR allows for generation of an arbitrarily angled cross-664 
section within the entire three-dimensional data set. Such MPRs allow a better visualization and appreciation of 665 
anatomical and pathological structures (49,53). Semi- or full automatic centerline (CL) analysis are used to 666 
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improve length measurement accuracy and to achieve diameter perpendicular to the CL (53).  Aortic diameter 667 
measurements must always be obtained using MPR reconstruction on planes perpendicular to the aortic flow 668 
direction (“double-oblique” technique) (54). 669 
 670 
Magnetic Resonance Imaging 671 
Magnetic resonance imaging (MRI) can provide 3D images of the aorta and surrounding structures with high 672 
contrast enhancement and high spatial resolution. MRI has obvious advantages over CT including superior soft 673 
tissue contrast, the absence of ionizing radiation, and the ability to depict and quantify functional parameters. 674 
Combining anatomical and functional information in a single acquisition means that MRI can potentially provide a 675 
more comprehensive evaluation of thoracic aortic disease. The relatively long acquisition times however limit its 676 
use in the acute setting. 677 
 678 
Magnetic resonance angiography (MRA) is the most commonly used MRI technique for both pre- and post-679 
procedural imaging of the thoracic aorta. CE (Contrast enhanced) MRA techniques rely on the T1 shortening 680 
effect of Gadolinium(Gd)-chelate contrast agents in blood to generate high intravascular signal, instead of 681 
exploiting the inherent motion of blood flow as in the flow-based time-of-flight (TOF) and phase-contrast (PC) 682 
techniques. Thanks to this different approach the vascular signal generated with CE-MRA is not hampered by the 683 
numerous flow-related artifacts that can degrade the flow-based MRA techniques (55,56). One of the more 684 
effective compounds for vascular contrast is Gd-BOPTA (Gadobenate dimeglumine), which has been proven to 685 
perform better than the standard compounds due to weak binding to serum albumin (57). Some issues were 686 
raised regarding the occurrence of a syndrome named nephrogenic systemic fibrosis (NSF), that limits the 687 
applicability of CE-MRA in patients with renal insufficiency (58). There is active research going on investigating 688 
the relevance of Gd-deposition in the human body after contrast enhanced exams, especially in the brain (59,60). 689 
Today, no clinical symptoms have been described associated with intracerebral Gd-deposition.  690 
 691 
The use of phased array coils provides the additional benefit of markedly shortening image acquisition times or, 692 
with the use of parallel imaging schemes, of acquiring higher spatial resolution image sets in the same time period 693 
(61,62). As with CTA, the vascular enhancement is a transient and dynamic process, hence the critical element to 694 
be set for a CE-MRA is the proper timing for the image acquisition.  695 
 696 
 697 
Dynamic MRA provides temporal information during the heart cycle that can be visualized as a dynamic display, 698 
thereby adding a fourth dimension, 4D CE-MRA. Its acquisition is typically combined with a Gd-based CM 699 
injection while a sequence of 3D volumes is acquired over time including fat suppression over time (49,63,64). 700 
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Fast GRE (Gradient echo)-sequence covers the entire aorta allowing high temporal resolution of e.g. 2-4s/volume 701 
and an interpolated spatial resolution of 1mm3 at a static magnetic field strength of 3 Tesla. This   fastest, time-702 
resolved MRA techniques are available, with two common acronyms for this approach: TWIST (time-resolved 703 
angiography with interleaved stochastic trajectories) and TREAT (time-resolved echo-shared angiographic 704 
technique) (65). 705 
 706 
 707 
Cranial magnetic resonance imaging can be used besides intracranial Doppler ultrasound (US) to assess Circle of 708 
Willis completeness, which helps predicting risk of insufficient cross-flow and stroke. Time-resolved MRA of the 709 
thoracic aorta is the optimal method to study mobility, stiffness and dynamics of dissection membranes, as well as 710 
resulting static or dynamic large vessel occlusion mechanisms. Similar to intracardiac flow dynamics in valvular 711 
disease, true and false lumen antegrade, retrograde and turbulent flows should be imaged using MRA as ‘gold 712 
standard’.  713 
 714 
 715 
Ultrasound  716 
US techniques have a low small-field-of-view (FoV) compared with CT and MRI. Ultrasound is also constrained 717 
by not being able to image through bone or gasses/ air but US can provide functional information with high 718 
temporal resolution. Contrast enhanced US (CEUS) is currently being performed using microbubbles as i.v. 719 
exogenous CM, e.g. for endoleak detection during endovascular aortic repair (EVAR) follow-up (66). Both 720 
trans-esophageal (TTE) and trans-thoracic echocardiography (TTE) can be performed bedside with a low 721 
incidence of complications. Using a variety of imaging projections, the aorta and its major branches can be 722 
visualized. More recently 3D techniques have been developed that can provide further information regarding 723 
the aorta and valve function although its clinical incremental value has not yet been fully assessed. 724 
Ultrasound can add important dynamic and functional insights in to the disease process at several 725 
levels also with regard to aortic branches of first order such as the supraaortic, visceral, renal and 726 
iliac/femoral vessels. 727 
 728 
Intravascular ultrasound (IVUS) provides dynamic information regarding both true and false lumen and allows to 729 
detect false lumen thrombosis with higher sensitivity and specificity than TEE. Because of its invasiveness, the 730 
use of IVUS is limited to intraoperative guidance.  731 
 732 
 733 
 734 
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 735 
Diagnostic Work-up in Aortic Arch Disease – Emergency Repair Setting  736 
The diagnostic workup in preparation of emergency aortic arch repair, in most cases acute Stanford Type A or 737 
non-A-non-B dissections, also focuses on selecting the most effective, most durable, and safest operative and 738 
perfusion strategy, however with less time available and a limited diagnostic workup of supraaortic and 739 
intracranial collateral flow. CTA, TEE in the operation theatre, and sometimes supraaortic Duplex US of carotid 740 
arteries are possible providing sufficient information to be able to plan and to treat. 741 
 742 
 743 
RECOMMENDATION 7 Preoperative assessment of aortic arch pathologies with Computed Tomography 744 
Angiography is recommended as first line imaging modality Class I Level C 745 
 746 
RECOMMENDATION 8 Assessment of patency and morphology of the circle of Willis is recommended where 747 
treatment involves the aortic arch Class I Level C 748 
 749 
RECOMMENDATION 9 Assessment of the extracranial supraaortic vessels down to the level of the femoral artery 750 
bifurcation is recommended where treatment involves the aortic arch Class I Level C 751 
752 
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 753 
4) Risk stratification, patient and treatment approach selection 754 
Risk constellations and case mix in patients with aortic disease are no less heterogeneous than in the cardiac 755 
surgical population. Currently available modalities for perioperative risk assessment like STS Risk Model for 756 
Mortality (STS-PROM) (67) or ES I and II (68) have been well validated for cardiac surgery, but not for aortic 757 
disease and its surgical and endovascular treatment options. Thus, STS-PROM and ES are inappropriate risk 758 
prediction tools for patients with aortic arch pathologies and procedures. The same holds true for other, 759 
unmodeled severity scores. 760 
 761 
Since clinical prediction models (CPM) are indispensable for any risk stratification in patients undergoing invasive 762 
procedures, their lack for aortic arch pathologies hampers comparison of prospective study results, database 763 
analyses, therapies and of institutional and health care systems performance. In this field, development of a 764 
dedicated CPM and risk score remains therefore an unmet need. In recognition of the increasing frequency and 765 
complexity of thoracic aortic medicine, the STS has recently formed a task force on aortic surgery and has added 766 
aortic pathology as a module in order to collect data for CPM development and further research (69). 767 
 768 
Patient selection and selection of the treatment approach-Aortic arch pathology in various extent without any 769 
further affection of the cardiovascular system is the exception and not the rule. Despite that several underlying 770 
pathologies leading to the final common path of aneurysmal formation/ lesion development, the algorithm to 771 
diagnose concomitant cardiac and vascular conditions should be standardized in all patients being evaluated for 772 
treatment and finally, outcome of this diagnostic algorithm should also have an impact on the final treatment 773 
strategy. 774 
 775 
Each patient should undergo TTE or in case of remaining need, TEE. Coronary angiography is recommended in 776 
all patients in need for open surgery whereas non-invasive testing might be regarded as sufficient in selected 777 
cases scheduled for endotherapy in the absence of symptoms indicative for coronary artery disease. In 778 
candidates for endovascular treatment with a past medical history of coronary artery disease, additional 779 
diagnostics should be considered to quantify the severity of the underlying concomitant condition. 780 
 781 
Supraaortic branches should be evaluated by supraaortic US and there is definitive need for evaluating 782 
cerebral cross-flow and the patency of the Circle of Willis. Finally, a CTA should evaluate the entire aorta 783 
including her branches of first order. Harmonization of the aforementioned diagnostic should then lead to a 784 
recommendation for treatment be it open surgery, combined vascular and endovascular procedures, a full 785 
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endovascular approach or to a recommendation for conservative treatment in case that the remaining risk of 786 
concomitant conditions outweigh the potential benefit of treatment. 787 
5) Monitoring during aortic arch repair 788 
As for any major cardiovascular surgery, standard monitoring includes non-invasive and invasive hemodynamic, 789 
respiratory, anesthesia, temperature, coagulation and laboratory monitoring. Additional monitoring techniques for 790 
aortic arch procedures should be selected according to specific requirements of patient, surgeon and 791 
interventionist, in order to help preserve hemodynamics and organ function, and to support procedural 792 
management (2). 793 
 794 
Transoesophageal Echocardiography 795 
TEE offers real-time 2D and 3D morphological and functional cardiovascular assessment as a semi-invasive 796 
imaging modality. Echocardiography systems used in aortic arch programs should include options and probes for 797 
epiaortic and epicardial US, for Doppler and 2D interrogation of supraaortic and peripheral vessels, as well as for 798 
US-guided vascular access. There is consensus in current guidelines that use of perioperative TEE is 799 
recommended for all adult open thoracic aortic surgical procedures, i.e., also those involving the aortic arch (70). 800 
Also, TEE is indicated in patients with suspected acute aortic syndrome who are unstable and are already 801 
intubated (70). 802 
 803 
During hybrid and endovascular thoracic aortic procedures, TEE should at least be available. Use of TEE may be 804 
considered, e.g., in dissection cases and when general anesthesia is provided, for purposes of procedural and 805 
instrumentation guidance, i.e., guidewire placement via the dissected aorta (71), endoleak assessment (71–74) or 806 
detection of cannulation injury. The benefit of TEE in these scenarios is less well supported by evidence than for 807 
perioperative use. Since some endovascular procedures may be performed under local anesthesia, anesthesia or 808 
increased sedation requirements for purposes of TEE monitoring are to be weighed against its incremental 809 
diagnostic benefit.  810 
 811 
Invasive arterial pressure monitoring 812 
During endovascular or surgical repair of aortic arch pathology, continuous monitoring of invasive arterial blood 813 
pressure is indicated. Selection of the monitoring site should take vessel pathology into account (e.g. dissection, 814 
stenosis, fistula, atheroma, anatomical variants), and must not interfere with vascular access and branch vessel 815 
manipulation. In endovascular procedures involving  the aortic arch, multiple arterial access sites via lower and 816 
upper extremities are usually required. The arterial site dedicated to anesthesia monitoring must therefore be 817 
chosen carefully in consultation with the performing team, and on an individualized basis. 818 
 819 
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Open surgical repair of the aortic arch requires periods of occlusion and selective perfusion of supraaortic 820 
branches at least temporarily and often sequentially. A single-site arterial line is not be sufficient  for uninterrupted 821 
monitoring of vital organ perfusion pressures. Bilateral invasive radial artery pressure measurement allows 822 
monitoring of cerebral perfusion pressure, without interruption during direct subclavian cannulation or during 823 
subclavian cross-clamping for cannulation and during repair. When right axillary antegrade cerebral perfusion 824 
(RAACP) is performed via a cannulated graft sewn to the artery, simultaneous monitoring of RAACP inflow 825 
pressure and resulting left radial pressure is possible. This may provide information about functional integrity of 826 
the Circle of Willis (75), and/or run-off blood flow from the LSA to the DTA (DTA). Nevertheless, bilateral radial 827 
pressure monitoring is used in aortic arch surgery only by about 50% of surveyed European centers (76).  828 
 829 
Additional femoral arterial (FA) pressure monitoring (preferably at the non-surgical or non-dissected FA) allows 830 
assessment of efficacy of distal body perfusion before and after  hypothermic circulatory arrest (HCA), and to 831 
detect post-repair pressure gradients across the arch. Particularly during rewarming from HCA and for several 832 
hours after termination of prolonged cardiopulmonary bypass (CPB) runs, radial pressure often underestimates 833 
central aortic pressure, which is better approximated by FA pressure. Due to vasodilatory arteriovenous shunting 834 
in the distal upper extremities, radial pressure may underestimate central aortic pressure (measured by direct 835 
needle transduction) by up to 20 mmHg mean and 35 mmHg systolic pressure (77,78). Overdiagnosis of 836 
“vasoplegic syndrome” or “vasodilatory shock”, with inadequate dosing of vasopressor agents, may be avoided  837 
by central aortic pressure verification and use of the FA for early postop pressure monitoring. 838 
 839 
For surgical repair of the aortic arch, bilateral invasive upper extremity arterial pressure monitoring should 840 
therefore be used routinely. In this type of surgery with prolonged CPB and periods of HCA, consideration should 841 
also be given to intermittent direct central aortic pressure reference measurement and / or additional FA pressure 842 
monitoring. 843 
 844 
NIRS-based regional oxygenation monitoring 845 
Near-infrared spectroscopy (NIRS) of hemoglobin fractions can be used to continuously monitor the balance of 846 
oxygen supply and demand in superficial cortical regions of the brain, i.e., by bifrontal NIRS-derived cerebral 847 
oximetry (79,80). The potential and the limitations have extensively been studied during carotid endarterectomy 848 
where the evidence to define clear cut-off points for the presence of perioperative cerebral ischemia still is limited 849 
(81). During aortic arch procedures, cerebral tissue Hemoglobin (Hb) may desaturate for a large variety of 850 
reasons, e.g., global or unilateral hypoperfusion (82) or cerebrovenous congestion; aortic or SACP cannula 851 
malposition, vessel dissection or malperfusion; systemic hypotension, hypoxemia, hypocapnia, hemodilution, 852 
anemia or low cardiac output; insufficient levels of hypothermia or anesthesia; aggressive rewarming  (83); or 853 
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other causes of regional or global ischemia. If this monitoring modality is used, differential diagnosis and the use 854 
of an algorithmic approach to intervention for regional cerebral tissue Hb desaturation is recommended (84,85).  855 
 856 
A survey of 144 European cardiac centers found that NIRS oximetry is used in arch surgery by 65% of institutions 857 
(76). It also showed that NIRS oximetry has largely replaced invasive jugular bulb oximetry (76,86). An analysis of 858 
open arch surgical strategies at 12 large European centers reported NIRS use for neuromonitoring in all centers 859 
(87). The limitation remains that uneventful intraoperative bifrontal rSO2 (regional cerebral oxygen saturation) 860 
tracings do not rule out focal cerebral ischemia, which may occur outside the limited field of view of current NIRS 861 
devices. Transcranial Doppler monitoring presents another option to monitor changes in cerebral perfusion but is 862 
more complex with regard to the setup and the application during aortic arch surgery. 863 
 864 
So far there is only low-grade evidence in adult cardiac surgery (85,88–94), and moderate-grade evidence in 865 
thoracic aortic surgery that links intraoperative cerebral rSO2 desaturation to postoperative new neurological 866 
morbidity (83,95–97). Nevertheless, with its perceivably favorable risk-benefit ratio, routine use of non-invasive 867 
continuous NIRS monitoring during thoracic aortic procedures is increasing (76,87,98–100). For surgical and 868 
hybrid repair of aortic arch pathology, NIRS-based continuous monitoring of rSO2 is recommended in combination 869 
with an algorithmic approach to intervention for desaturation events (84,96) . Good evidence for a benefit of NIRS 870 
monitoring in endovascular arch repair is still lacking. Indications for its use are pragmatically inferred from 871 
surgical (carotid, arch) and stroke populations (99,101,102). NIRS-based continuous monitoring of rSO2 should 872 
therefore be considered at an opinion-based level of evidence. 873 
 874 
Central nervous system electrophysiological function monitoring 875 
Electroencephalography (EEG) (raw or more commonly, processed to parametric display) has been widely used 876 
in aortic arch surgery to ensure electrical and cerebral metabolic suppression, to a level of complete electro 877 
cerebral inactivity (ECI) prior to HCA. This appears helpful in view of the considerable inter-individual variability in 878 
cooling efficacy and ischemic risk (103). Cooling time to cortical isoelectricity is not precisely predictable from 879 
tympanic or nasopharyngeal temperature trends, since ECI may ensue within a wide range of temperature, i.e. 880 
between 27.2° and 12.5° nasopharyngeal temperature (104). The strategy of HCA with hypothermia-induced ECI 881 
has produced increasingly good neurological and survival outcomes over time (105), but evidence as to the 882 
incremental benefit from EEG monitoring per se remains scarce.  883 
 884 
 885 
Nowadays, the strategy of open aortic arch surgery increasingly shifts to using moderately HCA (>/= 28°C 886 
systemic) combined with hypothermic SACP (106–111), with comparably good major outcomes and lower stroke 887 
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rates (109). With this strategy, hypothermic EEG silence is no more targeted during cooling, and EEG monitoring 888 
refocuses on detection of ischemia and inadequate anesthetic levels as in other surgical fields. Still, the choice of 889 
lower core temperatures should be considered for having a sufficient safety margin according to the expected 890 
lower body circulatory arrest time 891 
 892 
European and German surveys report that EEG is monitored in arch surgery by a third of polled centers (16%-893 
38%) (76,98). Bilateral EEG has been shown anecdotally to indicate inefficacy of SACP during moderately HCA 894 
(112). Further evidence is lacking so far that EEG monitoring improves major outcomes of arch surgery with 895 
SACP, or of hybrid or endovascular arch repair. Since its incremental benefit in surgical or endovascular repair of 896 
aortic arch pathology is established only by opinion and low-grade evidence, EEG or processed EEG monitoring 897 
may be considered according to institutional preferences (e.g. use of HCA) and concomitant indications (carotid 898 
crossclamping, monitoring of anesthetics effect).  899 
 900 
Monitoring of motor (MEP) or somatosensory evoked potentials (SSEP) can be useful in TAA and thoraco-901 
abdominal aortic surgery or endovascular repair in order to guide therapy and to allow early intervention in the 902 
anesthetized patient (113–116). A metaanalysis confirmed the good performance of MEP monitoring in detecting 903 
postoperative paraplegia in thoracic and/ or thoracoabdominal (TAA/TAAA) open repair (117). Both MEP and- 904 
less well investigated- SSEP neuromonitoring have been found useful in prevention and prediction of paraplegia 905 
(118,119). In a retrospective analysis, MEP has been found useful in simultaneous arch and thoracoabdominal 906 
aortic surgery as part of a protocolized brain and spinal cord protection bundle (120). Selective use of MEP and 907 
SSEP monitoring in aortic arch surgical or endovascular repair may therefore be considered based on 908 
requirements of the individual patient, surgery or procedure, on the urgency of the procedure and institutional 909 
resources (2).  910 
 911 
During hybrid arch repair, considerations of extracranial cerebrovascular surgery in anesthetized patients apply, 912 
while aortic arch debranching is performed without CPB. During this period, monitoring for cerebral ischemia 913 
according to institutional preferences (EEG or SSEP and/or NIRS) should be considered (99,101,121). 914 
Subsequent thoracic endovascular aortic repair (TEVAR) deployment may compromise spinal cord collateral 915 
perfusion. Depending on the extent of coverage and compromise of collateral flow, MEP or SSEP monitoring 916 
during this period should be considered in selected patients to assess integrity of spinal cord function (103).  917 
 918 
 919 
Spinal cord perfusion pressure monitoring and lumbar cerebrospinal fluid drainage  920 
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Distal aortic arch repair involving the DTA and use of the FET may compromise the collateral vascular network, 921 
and hence perfusion, of the spinal cord. Segmental spinal artery inflow may become impaired depending on flow 922 
characteristics in dissection and the extent of coverage by stent-grafts (122,123). Known contributors to spinal 923 
cord injury (SCI) are perioperative arterial hypotension, previous abdominal aortic aneurysm (AAA) repair and 924 
loss of LSA inflow (124). A systematic review reported a SCI incidence of 5.1% following FET deployment (125). 925 
To date, evidence is insufficient for a recommendation to use prophylactic MEP and/or cerebrospinal fluid (CSF) 926 
pressure monitoring and drainage in aortic arch repair with the use of FET (125,126). However, the use of lumbar 927 
CSF pressure monitoring and drainage may be considered based on individualized risk assessment for spinal 928 
cord ischemia (127,128). In situations of delayed SCI, selective secondary insertion of drainage as part of a 929 
treatment bundle is recommended (126,129). As imaging is still not able to provide us with a detailed description 930 
of intraspinal collateralization, which might be the answer who is at increased risk for SCI, risk prediction models 931 
remains approximations such as the collateral network concept and- developed on that basis- the four territory 932 
concept (130,131). 933 
 934 
CSF drainage management- CSF pressure is measured in mmHg in the majority of settings (since invention of 935 
electronic pressure transducers): cm H2O and mmHg are not “close in numbers” but enjoy a firm relationship (1 936 
cmH20 = 0.735 mmHg). Spinal perfusion pressure (SPP = MAP-CSFP, or -CVP whichever is higher) can only be 937 
determined correctly if arterial and CSF pressure transducers are referenced to the same level (phlebostatic axis 938 
= right atrial level) and unit of measurement:  939 
Hence, mmHg makes more sense, too, although some drainage systems give parallel scales in mmHg and 940 
cmH2O (e.g. Medtronic Duet® External Drainage & Monitoring System). After placement, a normal CSF opening 941 
pressure is 5-18 mmHg, and CSF may be drained to a target CSFP of 10-12 mmHg, as long as there is no SCI.   942 
 943 
Some institutions target the normal preoperative opening pressure, measured on catheter placement, as the 944 
individual baseline pressure (124) unless there is reason to suspect spinal cord injury. 945 
Drainage should always occur slowly, large bolus CSF withdrawals must be avoided.   If SCI occurs, reasonable 946 
CSF pressure targets are 8-10 mmHg, with limits on “volume” flow at 40 ml/4 hours, although some groups drain 947 
even lower to 7 or 5 mmHg, and larger volumes (≤ 20 ml/h) (132). 948 
But there is a clear risk (approximately 1%) of overdraining, intracranial hypotension and consecutive brain 949 
damage (subdural hematoma or hygroma, intracranial hemorrhage, brain herniation). 950 
 951 
 952 
Multisite Temperature Monitoring 953 
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During CPB, temperature gradients between different monitoring sites (nasopharyngeal, bilateral tympanic, 954 
bladder or Recommendationtal) develop temporarily during cooling and rewarming, and have to be taken into 955 
consideration (133). During open aortic arch surgery, monitoring of nasopharyngeal and tympanic temperatures is 956 
Recommendationommended to ensure adequate brain cooling, and to prevent cerebral hyperthermia and 957 
associated central nervous system (CNS) injury during rewarming (83,134,135). Additionally, bladder core 958 
temperature provides the best information available on to protection of the viscerals, renals, lower extremities and 959 
finally the spinal cord. 960 
 961 
Point-of Care Coagulation Monitoring   962 
Surgical as well as endovascular aortic arch repair requires reversible anticoagulation with unfractionated heparin 963 
(UFH). Although open surgery on CPB carries a substantially higher risk of major blood loss and transfusion, 964 
bleeding complications increase morbidity and mortality with either approach. Both procedural anticoagulation and 965 
postoperative hemostasis require laboratory monitoring to minimize both hemorrhagic and thrombotic 966 
complications. The whole-blood activated clotting time (ACT) test is a functional point-of-care (POC) method, 967 
which is recommended to guide UFH anticoagulation, as well as its reversal with protamine and is indicated as a 968 
minimum requirement during surgical, hybrid or endovascular aortic arch repair.  969 
 970 
 971 
ACT is not highly specific for UFH activity, however, and may be confounded by hypothermia, hemodilution, loss 972 
of platelets and of coagulation factors (136) all of which typically occur during aortic arch open surgery. Therefore, 973 
and in accordance with 2017 EACTS/EACTA (European Association for Cardio-thoracic Anesthesia) Guidelines 974 
for Patient Blood Management, heparin management for arch surgery with prolonged CPB and HCA should 975 
consider to use quantitative monitoring of circulating UFH concentrations rather than simple serial ACT 976 
measurement (137). 977 
 978 
Whole-blood viscoelastic coagulation test systems (thromboelastography-TEG rotational thromboelastometry- 979 
ROTEM) provide POC analysis of clot generation and stability with short response time. In conjunction with 980 
treatment algorithms, they have been shown to be helpful in differential diagnosis and treatment of post-CPB 981 
bleeding (138). Moderate-level evidence from trials of elective cardiac surgery with CPB indicates that use of 982 
TEG- or ROTEM-guided transfusion strategies may reduce exposure to allogeneic blood products (139–141) and 983 
possibly surgical re-exploration for bleeding (137,142,143). In aortic arch open surgery, viscoelastic POC testing 984 
should be considered, in conjunction with perioperative treatment algorithms for bleeding patients, in order to 985 
reduce allogeneic transfusion exposure and cost.  986 
 987 
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RECOMMENDATION 10 988 
- TEE is recommended during all open thoracic aortic surgical procedures. Class I Level B (70)  989 
- TEE is recommended in all unstable intubated patients with suspected acute aortic syndrome.  Class I 990 
Level B (70) 991 
- TEE should be available in hybrid and endovascular thoracic aortic procedures.  Class IIA Level B (71) 992 
RECOMMENDATION 11 During surgery for aortic arch repair,  993 
- bilateral invasive upper extremity arterial pressure monitoring should be considered. Class IIA Level C 994 
- femoral arterial pressure monitoring should be considered. Class IIA Level C 995 
- intermittent direct central aortic pressure reference measurement should be considered. Class IIA Level 996 
C 997 
 998 
RECOMMENDATION 12 During surgery for aortic arch repair, it is recommended to use bilateral NIRS-based 999 
cerebral oximetry combined with an algorithmic approach to intervention for cortical Hb-Desaturation. Class I 1000 
Level B (82–87,95–99,144–146)  1001 
 1002 
RECOMMENDATION 13 In situations of delayed SCI, selective secondary insertion of a CSF drainage as part of 1003 
a treatment bundle is recommended. Class I Level C 1004 
 1005 
RECOMMENDATION 14 During surgery for aortic arch repair, multisite temperature monitoring (at a minimum 1006 
nasopharyngeal, tympanic, bladder or rectal probe) is indicated. Class I Level B (83,134,135) 1007 
 1008 
RECOMMENDATION 15 During aortic arch surgery, point-of care coagulation monitoring in conjunction with an 1009 
algorithmic approach to transfusion of blood products should be considered. Class IIA Level A (137,140–143) 1010 
1011 
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 1012 
6) Therapeutic options- Open aortic arch replacement  1013 
 1014 
Open aortic arch replacement involving all three supraaortic branches without the adjunct of either elephant trunk 1015 
(ET) repair or in combination with the FET technique has become rare (147,148) (Figures 4 and 5).  The ET 1016 
technique should be applied when the FET technique remains debatable. For instance, in large aneurysmal 1017 
formations, involving several thoracoabdominal (TA) segments and in very small true lumina with the risk of 1018 
inducing pseudocoarctation), a FET procedure is not recommended. 1019 
 1020 
 1021 
The ET technique with and without sewing collar solutions is an optimal solution when secondary surgical TA 1022 
replacement is to be anticipated. The woven polyester is an ideal fabric to be clamped and to be sewn to with a 1023 
downstream aortic graft for open descending thoracic or TA replacement. On the other hand, the ET can serve as 1024 
an ideal landing zone for TEVAR extension if the ET is long enough. Therefore, a sufficient length is advisable. A 1025 
clip at the end of the polyester graft can simplify cannulation during fluoroscopy. Retrograde perfusion of an ET 1026 
via the femoral artery is not recommended as this might push the ET into the aortic arch and potentially obstruct 1027 
supraaortic vessels. Therefore antegrade perfusion via the right subclavian/ axillary artery or via side-branch is 1028 
recommended. In residual dissection after type A repair, the dissection membrane is usually removed as distal as 1029 
can at least for the length of the ET so that the ET floats in the common proximal lumen. 1030 
 1031 
 1032 
However, it should be mentioned that the ET portion should be left adequately long to be accessible in zone 4 in 1033 
order to serve as a platform for either open surgical or endovascular extension. Regarding the level of the 1034 
descending aortic anastomosis, in parallel to the FET technique, a proximalization of the anastomosis into zone 2 1035 
eases accomplishment as well as bleeding control. Additionally, the risk of left laryngeal nerve palsy is reduced 1036 
Finally, a double layer running suture or a strip of tissue will reinforce the anastomosis and will reduce the need 1037 
for correction stitches for hemostasis. 1038 
 1039 
With regard to supraaortic vessels, selective replantation has the advantage of eliminating the largest amount of 1040 
native tissue thereby potentially reducing the risk for recurrence. A variety of branched grafts is available and 1041 
should be used according to experience and preference.  1042 
 1043 
 1044 
RECOMMENDATION 16 In case of elephant trunk (ET) implantation, the polyester trunk component should be 1045 
accessible in zone 4. Class I Level C 1046 
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RECOMMENDATION 17 An anticipative strategy with regard to potential future operations or interventions is 1047 
recommended in any scenario of proximal aortic repair where later secondary distal repair may be needed. Class 1048 
I Level C 1049 
 1050 
RECOMMENDATION 18 In case of ET, the distal anastomosis should be considered to be performed in aortic 1051 
arch zone 2 in order to easen accomplishment and to facilitate bleeding control. Class IIA Level C 1052 
36 
 
 1053 
7) Therapeutic options- FET  1054 
 1055 
FET combines the principles of open arch surgery and endovascular DTA repair (Figure 6). The extension of arch 1056 
replacement into the DTA by a separated stent-graft was first introduced clinically by Dr. Masaaki Kato in October 1057 
1994. However, it was not until November 1996 that Dr. Kato reported his experience with this technique in 10 1058 
patients (149,150). The technique has been used in Europe since 2001 (151,152).  1059 
 1060 
 1061 
The technique is called Frozen Elephant Trunk following the development of a combined vascular and stent-graft 1062 
prosthesis in one fashion (153). Similar to the ET technique, a stent-graft is introduced through the opened arch 1063 
into the DTA enabling the exclusion of distal arch pathologies in one step. The proximal part of the graft is used 1064 
for conventional arch replacement. The breakthrough for the widespread application of this technique occurred in 1065 
year 2005 with the development of the first commercially available hybrid prosthesis, the so called E-vita open™, 1066 
(154).  As a tube fabricated vascular graft is invaginated into a stent-graft according to the principle of the 1067 
modified ET technique (155) and the whole graft is delivered and deployed into the DTA with an endovascular 1068 
introducer.  The FET armamentarium is completed by a branched hybrid graft, so called Thoraflex™, which 1069 
enables the reimplantation of the supraaortic vessels separately using three prefabricated vascular branches 1070 
(156). A side graft allows direct cannulation for antegrade distal perfusion during the arch replacement. There are 1071 
two other commercially available FETs, the Cronus (MicroPort, Shanghai, China) and the J graft (now Frozenix) 1072 
(Japan Lifeline, Tokyo, Japan) (157,158)  1073 
 1074 
The indication of FET covers all  pathologies of the aortic arch, aneurysm and dissection (159–161). Different 1075 
from endovascular aortic repair, the fixation of FET is performed by a circumferential suture, which eliminates the 1076 
risk of proximal endoleak. The endoluminal sealing of the surgical suture line by the stent-graft improves 1077 
hemostasis and makes FET ideal to fix a fragile aortic tissue.  This combination of surgical suture and 1078 
endovascular sealing enables the durable exclusion of antegrade false lumen perfusion in acute and chronic 1079 
aortic dissection as well as aneurysmal cavities without excessive oversizing of the stent-graft. Particularly in 1080 
acute aortic dissection a progressive false lumen thrombosis in more than 90% followed by shrinkage and positive 1081 
remodeling has been reported from several studies (162,163). The potential exclusion of the downstream aortic 1082 
pathology occurs predominantly up to the distal end of the stent-graft, so that FET can be applied curatively only 1083 
in association with the extension of thoracoabdominal aortic disease in many scenarios. Patients with residual 1084 
aortic pathology beyond the FET remain at risk for secondary treatment. However, shifting the treatment level by 1085 
the stent-graft to at least a mid-thoracic level facilitates secondary treatment by using the stent-graft as landing 1086 
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zone for endovascular or as a docking place for open surgical repair. In case of open TA repair, the capability of 1087 
the stent-graft to be clamped provides an easier surgical access to perform the anastomosis beyond the arch with 1088 
less necessity of rib resection, HCA and no risk for laryngeal nerve injury (164,165). However, the texture of the 1089 
fabric of endovascular/ FET devices is by nature thinner and prone to fabric tears when an anastomosis is directly 1090 
performed to a conventional polyester graft. Therefore, the suture should include the aortic wall as well as good 1091 
as can. 1092 
 1093 
In case of endovascular reintervention the stent-graft component provides a safe landing zone for distal 1094 
extension. Thus, FET can be used in type I and II TAAAs as a first stage procedure when primary proximal 1095 
sealing cannot be achieved adequately by endovascular means. In this case, sizing and length of FET should be 1096 
planed considering the requirements of the second endovascular procedure in order to avoid excessive mismatch 1097 
and a multicomponent secondary endovascular intervention. Generally, FET deployment beyond the transition 1098 
Zone 4-5 provides a safe length for additional stent-graft deployment and easier retrograde access in case of 1099 
severe aortic tortuosity. However, care has to be taken in order to avoid extensive covering, which is reported to 1100 
be associated with increased risk for SCI (166,167).    1101 
 1102 
The technique of FET is similar to classic ET and represents major surgery. Sophisticated cannulation and 1103 
perfusion techniques have been introduced in order to make antegrade selective cerebral perfusion as safe as 1104 
can, to reduce lower body HCA times to a minimum and to improve organ protection in general. Considering the 1105 
sealing properties of the stent-graft, the proximalization of FET fixation from Zone 3 to Zone 2 facilitates the distal 1106 
anastomosis and reduces the duration of lower body HCA as well as the risk for laryngeal nerve injury (168,169). 1107 
Combination of FET with LSA debranching minimizes the duration of arch repair and allows the perfusion of all 3 1108 
arch vessels for additional cerebral and spinal cord protection. The implementation of selective distal perfusion 1109 
during arch repair using a side graft or balloon cannulas as endoclamp within the FET reduces lower body 1110 
circulatory arrest times and thereby improves distal organ protection. In addition, selective myocardial perfusion 1111 
during arch repair (“heart beating” concept) is used to reduce cardioplegic arrest times and to allow more 1112 
extensive proximal surgical procedures (170).  1113 
 1114 
To secure FET treatment the use of a guide wire, preferably via the FA under angiographic or echocardiographic 1115 
control may be of help. In aortic dissections, the wire secures FET deployment within the true lumen. In 1116 
aneurysms, it facilitates the guidance of FET over thrombus formation and aortic tortuosity avoiding debris 1117 
mobilization and distal embolization. Angioscopy represents an additional intraoperative tool in visualizing the 1118 
landing zone and endoluminal obstacles and in controlling the deployment downstream (171). Fluoroscopy during 1119 
FET introduction is usually not needed but can be helpful. 1120 
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 1121 
FET treatment is critical in acute and chronic aortic dissection with completely depended visceral arteries 1122 
perfusion from false lumen. In these scenarios, preoperative verification of patent communications between 1123 
lumina is recommended to avoid malperfusion. In connective tissue disease, the use of stent-grafts is 1124 
controversial and basically discouraged; in any case avoidance of oversizing is recommended. In DTA rupture a 1125 
safe distal landing zone for definitive sealing is a prerequisite for FET treatment. The TEVAR component of the 1126 
FET prosthesis cannot be equally interpreted as a “TEVAR-alone” approach in patients with connective tissue 1127 
disease as the remaining risk of distal stent-graft induced new entry is different in clinical weight and need for 1128 
correction than a proximal stent-graft induced new entry or in other words- retrograde type A aortic dissection 1129 
(172,173). Recently, EACTS has formulated recommendations for use of the FET technique (174).  1130 
 1131 
 1132 
 1133 
RECOMMENDATION 19 The FET technique or TEVAR to close the primary entry tear should be considered in 1134 
patients with acute type A aortic dissection with a primary entry in the distal aortic arch or in the proximal half of 1135 
the DTA to treat associated malperfusion syndrome or to avoid its postoperative development. Class IIA Level C 1136 
 1137 
RECOMMENDATION 20 The FET technique may be considered for use in patients undergoing surgery for acute 1138 
type A aortic dissection to prevent mid-term aneurysmal formation in the downstream aorta. Class IIB Level C 1139 
(174)(111)  1140 
 1141 
RECOMMENDATION 21 The FET technique should be considered in patients with complicated acute type B 1142 
aortic dissection when endovascular interventions are contraindicated. Class IIA Level C (161,175,176) 1143 
 1144 
RECOMMENDATION 22 The FET technique should be considered in patients with concomitant distal thoracic 1145 
and thoraco-abdominal aortic disease that, in a later stage will or is likely to require either surgical or 1146 
endovascular treatment. Class IIA Level C 1147 
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 1148 
8) Therapeutic options- Transposition (debranching) of supraaortic vessels and TEVAR and the 1149 
importance of the LSA in spinal cord blood supply 1150 
 1151 
Hybrid arch repair (or combined vascular and endovascular treatment) is a combination of both open and 1152 
endovascular procedures aimed to treat aortic arch disease. The core principle behind this treatment relies on 1153 
endovascular exclusion of the pathology following the creation of an adequate proximal landing zone (in zone 0, 1 1154 
and 2) (1) by means of supraaortic transposition (debranching) of one (LSA), two (and LCCA) or three (and IA, i.e. 1155 
total aortic arch debranching) arch vessels (Figures 7-9) .  1156 
 1157 
Debranching options are multiple and can be performed by means of anatomical or extra-anatomical 1158 
revascularization, with extrathoracic or intrathoracic approaches. The techniques presented in literature are 1159 
pleiomorphic: from aortic patch reimplantation, to branched or simple grafts interposition and autologous 1160 
transposition (177). Open and endovascular procedures can be performed simultaneously or with a staged 1161 
approach (open debranching first and endovascular exclusion as a second stage) according to need and 1162 
preference (178,179). TEVAR in the aortic arch should  be performed preferrably with a fixed imaging system. 1163 
 1164 
The main potential advantage of the hybrid approach is the avoidance of aortic cross-clamping, HCA, and CPB 1165 
with the potential risk reduction) in higher risk patients with proximal thoracic aortic pathology (zone 0 proximal 1166 
neck). For patients at higher risk of stroke open aortic arch surgery remains the best therapeutic option as 1167 
extensive manipulation during debranching as well as during TEVAR might cause embolization (178,180,181). 1168 
Patients presenting with distal arch pathology (zone 1 and 2 proximal neck) should be considered for an 1169 
endovascular approach with prior LSA and/or LCCA revascularization, if anatomically suitable.  1170 
 1171 
The devices employed for aneurysm exclusion are commercially available stent-grafts mostly designed for the 1172 
treatment of DTA pathology. The Instructions For Use of these devices require deployment in a proximal and 1173 
distal landing zone (native aorta or pre-existing graft) with a length ≥25mm, measured on the inner curvature, and 1174 
a diameter <38mm, measured according to manufacturer recommendations (inner/inner vs outer/outer diameter) 1175 
(182). Application of such devices in patients affected by connective tissue disease is contraindicated unless both 1176 
landing zones are within a previous surgical/endovascular graft (183). Moreover, at least one adequate (>7mm) 1177 
access vessel is required for successful stent-graft insertion, and the aortic lumen characteristics should be taken 1178 
into consideration to decrease the risk of embolization during advancement of the device in the aortic arch (e.g. 1179 
shaggy aortas, floating thrombi, severe calcifications) (184). Possible limitations of the hybrid approach are the 1180 
lack of inflow vessel for debranching (i.e. calcific/aneurysmatic ascending aorta), and the presence of unsuitable 1181 
landing zones length/diameter or narrow access vessels, inadequate for stent-graft introduction. Open repair 1182 
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should be considered in these cases as well as in cases at high risk of retrograde dissection (ascending 1183 
aorta>38mm, bicuspid aortic valve, arch abnormalities, lost sinutubular junction, extended ascending aortic 1184 
length). 1185 
 1186 
Furthermore, the hybrid approach carries risk of SCI due to the covered length of the DTA. For this reason, CSF 1187 
drainage should be employed in patients with increased risk (e.g. previous aortic surgery, occluded 1188 
hypogastric/subclavian arteries) (188–190. Also in hybrid procedures, current literature supports centralization in 1189 
centers with adequate volume and expertise (7). 1190 
 1191 
 1192 
Importance of the LSA in spinal cord blood supply-  1193 
 1194 
The main reason for prophylactic LSA revascularization prior to TEVAR is maintaining posterior cerebellar 1195 
perfusion as well as maintaining upper inflow into the anterior spinal artery and thereby spinal cord. There is 1196 
convincing evidence that the combination of LSA occlusion and extensive coverage of thoracic segmental arteries 1197 
by TEVAR are associated with increased risk of SCI which is significantly lower when the LSA is preserved. This 1198 
becomes clear when the collateral network concept and consecutively the four territory concept is conceptually 1199 
applied (130,131,185–187). 1200 
 1201 
RECOMMENDATION 23 TEVAR in zone 0 after previous debranching may be considered in patients unfit for 1202 
open repair and suitable anatomy. Class IIB Level B (180,191) 1203 
 1204 
RECOMMENDATION 24 TEVAR  in zone 1 and 2 should be considered in patients with suitable anatomy Class 1205 
IIA Level B (4) 1206 
 1207 
RECOMMENDATION 25 Stent-graft deployment is not recommended in patients with a proximal and/or distal 1208 
landing zone length less than 25mm or a maximum diameter of more than 38mm. Class III Level B (4,191) 1209 
 1210 
RECOMMENDATION 26 Zone 0-2 TEVAR is not recommended in patients with connective tissue disease if the 1211 
proximal landing zone is in native aortic tissue. Class III Level C 1212 
 1213 
RECOMMENDATION 27 Open aortic arch repair should be considered in patients with concomitant aortic valve 1214 
pathology or at high risk for retrograde type A aortic dissection (ascending aorta>38mm, bicuspid aortic valve, 1215 
arch abnormalities, lost sinutubular junction, extensive ascending aortic length). Class IIA Level B  (175,191) 1216 
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 1217 
RECOMMENDATION 28 In elective TEVAR in zone 0,1,2, preventive left subclavian artery revascularization 1218 
should be considered to reduce the risk of neurological complications such as stroke and spinal cord ischemia 1219 
Class IIA Level B  (152,171)  1220 
 1221 
RECOMMENDATION 29 Hybrid aortic arch repair should be centralized in centers with adequate volume and 1222 
expertise in both open and endovascular surgery. Class I Level C   1223 
1224 
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 1225 
9) Therapeutic options- Total endovascular repair  1226 
 1227 
The development of new endovascular techniques to treat aortic arch aneurysms has mitigated the risks 1228 
associated with open surgery and offers repair to patients that historically cannot undergo open repair. Early 1229 
experience using external branch endo-grafts suffered from high stroke rates, and were not adopted in the global 1230 
market (171-174). The subsequent development of arch endo-grafts with specific delivery systems, preloaded 1231 
fenestrations and inner-branches in recent years has improved results to a level that endovascular arch repair has 1232 
today become a viable option for patients with increased risk for open repair (Figure 10). 1233 
 1234 
 1235 
In contrast to more stable segments of the aorta, where endovascular treatment has become the standard of 1236 
care, the ascending aorta is characterized by high velocity and consequent shear stresses, four-dimensional 1237 
pulsatile and rotational movements during the cardiac and respiratory cycles, and the proximity of the coronary 1238 
ostia and aortic valve.  Endovascular arch repair requires a stable proximal landing zone within a surgical graft or 1239 
native ascending aorta with a diameter of 38mm or less. Larger diameters are prone to retrograde dissection and 1240 
thus should be avoided (196). The proximal sealing-zone should preferably have a length of 30mm or more 1241 
measured at the inner curvature that is free of excess calcification and thrombus, and angulation >60°.  1242 
 1243 
 1244 
Stroke remains a major concern during endovascular arch repair, with rates between 0 and 14% (176-181).The 1245 
mechanism of stroke includes solid emboli released by manipulation in the arch, air emboli released from the 1246 
delivery system, and coverage of the target vessels (193). To minimize the stroke risk, temporary carotid artery 1247 
occlusion, filter placement and carbondioxide flushing of the delivery-system has been proposed (193,194,200).  1248 
 1249 
For endovascular aortic arch repair, there are two general graft designs: fenestrated and branched arch endo-1250 
grafts. Both designs are currently available as custom made devices only, so manufacturing time of between 4 1251 
and 8 weeks precludes its use in urgent and emergency situations.  The current two inner branches design may 1252 
however become a future platform of an “off the shelf” branched stent-graft that will be used in emergency 1253 
situations. 1254 
 1255 
 1256 
Fenestrated arch endo-grafts can incorporate multiple fenestrations or a combination of fenestrations and 1257 
scallops. Graft apposition to the aortic wall at the level of the fenestrations is required for endovascular seal. The 1258 
sealing zone therefore is usually in the mid-arch at the level of the branch-vessels. Due to the distance from the 1259 
43 
 
femoral access vessels and the curvature of the arch, rotation of the fenestrated graft cannot be controlled, so 1260 
precision of placement relies on meticulous preoperative planning and the use of precurved delivery systems and 1261 
pre-loaded catheters that allow wires to be passed via these catheters and snared from upper extremity access. 1262 
 1263 
The largest cohort of fenestrated arch repair from Japan used a pre-curved fenestrated stent-graft (Najuta-graft) 1264 
without preloaded wires in 363 patients with a landing zone in the ascending aorta and reported a 1.6% 30d-1265 
mortality and 1.8% stroke rate (201). This system does not use bridging stents to fixate the fenestrations at the 1266 
target-vessel ostia. The Zenith fenestrated arch endo-graft (Cook Medical, Brisbane, Australia) uses a preloaded 1267 
wire system combining usually a fenestration and a scallop using a covered bridging stent to fixate the 1268 
fenestration to the left LCCA or LSA as target vessel. Small published series representing early experience have 1269 
reported mortality up to 20% and stroke rate up to 14% (192,202). The Relay scalloped endo-graft (Terumo 1270 
Aortic) does not include fenestrations, preloaded catheters or the use of covered stents for the target-vessels and 1271 
is mainly used for zone 2 and 3. In a single reported small series mortality was 5% and stroke rate 14% (197). 1272 
Stroke remains a major concern in any kind of open or endovascular aortic arch treatment strategy and 1273 
can be seen as the major important challenge to address in the years to come. 1274 
 1275 
Branched arch endo-grafts currently include antegrade or retrograde internal side-branches along the outer curve 1276 
of the stent-graft. The two currently available platforms in Europe aiming at seal in the ascending aorta both use 2 1277 
antegrade inner-branches to be connected to the IA and to the LCCA while the LSA is usually debranched in a 1278 
staged procedure (193). This design requires less precision in placement compared to fenestrated arch endo-1279 
grafts as distance between the branch openings and the target-vessels allows for continued perfusion of the 1280 
supra-aortic vessels after main-graft deployment and a simplified catheterization of the inner-branches. 1281 
 1282 
The Zenith branched arch endo-graft (Cook Medical, Brisbane, Australia) includes a staged proximal release 1283 
mechanism. Early experience has been reported with no 30d mortality and a stroke rate of 11% (199). The Relay 1284 
branched arch endo-graft (Bolton Medical, Barcelona, Spain) is built using two parallel inner-branches on the 1285 
Relay NBS platform using a proximal tip-capture. Early experience in a small series collecting global experience 1286 
showed a 7% mortality and a 7% disabling stroke rate (203). 1287 
 1288 
Branched endovascular arch repair is today increasingly used in patients after previous open ascending repair for 1289 
type A aortic dissection. The presence of a prosthetic graft in the ascending aorta acts as a favorable proximal 1290 
landing zone for an arch endo-graft, excluding risk of retrograde dissection and  > 70% of patients have a 1291 
proximal landing zone in the previous ascending aortic graft suitable for branched endovascular arch repair (204).  1292 
 1293 
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The TAG® single sidebranch endo-graft (Gore® Medical, Flagstaff, USA) and the Valiant™ Mona LSA single 1294 
sidebranch stent-graft (Medtronic Inc, Santa Rosa, USA) are arch endo-grafts with a single sidebranch aiming at 1295 
preservation of the LSA in Zone 2 TEVAR (205). Both endo-grafts are currently used in limited number of centers 1296 
with no clinical data published so far. 1297 
 1298 
At the present time, with careful patient selection and operator experience, early use of this technology presents 1299 
an alternative to open aortic arch repair or conservative therapy, respectively. 1300 
 1301 
 1302 
RECOMMENDATION 30 Endovascular aortic arch repair in zone 0 should be considered in patients unfit for open 1303 
surgery and with a suitable anatomy. Class IIA Level B  (199,203) 1304 
 1305 
RECOMMENDATION 31 It is recommended that endovascular aortic arch repair is performed in centers with 1306 
adequate volume and expertise of open and endovascular arch repair. Class I Level C   1307 
 1308 
RECOMMENDATION 32 In any open proximal thoracic aortic surgery, ascending/ hemiarch replacement has to 1309 
be extensive and short ascending grafts should be avoided for preventing disease progression and for 1310 
anticipating future endovascular modular distal extension.  Class I Level C   1311 
 1312 
1313 
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 1314 
10) Therapeutic options- Alternative approaches  1315 
Alternative approach to aortic arch pathologies are endovascular techniques applying the chimney graft (CG), the 1316 
periscope and sandwich technique (summarized as parallel grafts) and in-situ fenestration. Parallel grafts are 1317 
bare or covered stents deployed into one or more supraaortic vessels parallel to the main aortic arch stent-graft. 1318 
This allows extending the sealing zone of the aortic stent graft beyond the origin of the respective supraaortic 1319 
vessel. One of the first reported parallel grafts in the literature was used in 2003 (206) in a patient undergoing 1320 
EVAR to secure a renal artery in a patient with a very short proximal landing zone. The first parallel graft used in 1321 
aortic arch treatment was reported 2 years later (207). There are several modifications of the parallel graft 1322 
technology. The standard parallel graft is proximally oriented and allows antegrade flow up to an aortic branch. 1323 
The periscope parallel graft is distally oriented and blood flow is retrograde. The sandwich technique includes an 1324 
aortic stent graft deployed first as an artificial landing zone to implant the parallel grafts. After parallel graft 1325 
implantation another aortic stent-graft is deployed to exclude the entire pathology. The parallel grafts are located 1326 
between both aortic stent-grafts. Furthermore, parallel grafts can be used only to compress the graft edge to 1327 
secure the flow into the vessel where the parallel graft was implanted. Parallel graft are used as a bailout when 1328 
target vessels are incidentially covered to allow very aggressive stent graft placement in case of short landing 1329 
zones 2 and 3.  1330 
 1331 
There are several advantages of parallel graft techniques when compared with fenestrated or branched stent 1332 
grafts. First of all, parallel grafts are available off the shelf. Fenestrated and branched stent grafts are mostly 1333 
customized and usually manufacture time takes 1-3 months. They are clearly not an option in patients requiring 1334 
emergent or urgent aortic arch repair. Second, parallel grafts are less expensive than fenestrated and branched 1335 
stent grafts. Furthermore, there is a large experience of visceral CGs available in the literature with acceptable 1336 
results especially in patients requiring urgent aortic repair (208). However, the literature on supraaortic parallel 1337 
grafts is scarce. Results of visceral parallel grafts are most probably not representative for expected results of 1338 
supraaortic parallel grafts. 1339 
 1340 
Parallel graft techniques carry a risk of endoleak Type I due to the so-called gutters, which are channels between 1341 
the parallel graft and the main aortic stent graft. Those gutters are per definition inevitable, however not all of 1342 
them lead to endoleaks detectable in CTA. Even thrombosed lesions can still remain under pressure, if there are 1343 
gaps in the sealing zone. It may lead to endotension which is defined as pressure within the aneurysm sac 1344 
without evidence of endoleak as the cause. Endotension raises the risk of aneurysm rupture (209). Gutters 1345 
caused by parallel grafts are specifically relevant if pathology at the outer curvature is treated such as in most 1346 
cases of Type B aortic dissection, where gutters may cause Type 1A endoleak. If pathologies affecting the inner 1347 
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curvature are treated, gutters caused by parallel grafts on the outer curvature are less prone to cause type 1A 1348 
endoleak. 1349 
 1350 
Furthermore, stent-grafts were not designed for the parallel graft approach. The radial force, elasticity, shape and 1351 
even length of currently used stent grafts in parallel graft cases are not optimal. There are no covered stent grafts 1352 
dedicated for parallel graft techniques.  Additionally, numerical studies suggest worse hemodynamic 1353 
performances in parallel graft models when compared with surgical or hybrid arch repair models (210). Finally, to 1354 
avoid endoleak type 1 aortic stentgraft oversizing is necessary and for larger aortas aortic stent-graft with 1355 
appropriate diameter are not available (211). 1356 
 1357 
There are several reports on parallel graft in treatment of aortic arch or proximal DTA. The largest multicenter 1358 
series include up to 95 patients (212). The 30-day mortality ranges between 0 and 29% (including elective and 1359 
emergency cases (213–215) The overall early patency rate of parallel grafts ranges between 92 and 100% (178–1360 
180). Early endoleak type I was reported in a meta-analysis of 314 cases at the level of 11% (range, 0-44%) 1361 
(216). Forty-five percent of early endoleaks in this report sealed spontaneously. The follow-up in currently 1362 
available reports ranges between 1 and 30 months (212–216). There are no long-term follow-up data in these 1363 
patients. The number of re-interventions is provided in most reports, however in the vast majority of reports there 1364 
are no data on number of patients who require aortic arch repair due to the failure of parallel grafts. Finally and 1365 
most importantly in vast majority of reports there are no data on sac dynamics at follow-up. 1366 
 1367 
Parallel graft technology is a useful treatment option in patients requiring emergent or urgent aortic arch repair. 1368 
Parallel grafts can also be used as a bailout technique in case of accidental covering of a supraaortic vessel. 1369 
Parallel grafts should be avoided in elective cases with anatomy suitable for branched or fenestrated devices or 1370 
open surgery until more data with better quality than currently available exists. 1371 
 1372 
In-situ fenestration of standard stent grafts is another option to extend the proximal landing zone by covering the 1373 
supraaortic branches and performing a fenestration via a retrograde access in vivo (217,218). Graft perforations 1374 
can be performed by laser or mechanical means. This technique is new and long-term data in human are missing. 1375 
Currently in-situ fenestration is an off-label procedure that can be used only as an emergent bailout technique or 1376 
in the setting of investigational studies. Recent work demonstrates that both laser and mechanical in-situ 1377 
fenestration create substantial damage to all available stent-graft fabrics (219) . 1378 
 1379 
The multilayer (or flow modulator) technique has recently been advocated for the treatment of various thoracic 1380 
and abdominal aortic pathology including the aortic arch. The principle of the technique is formed by a self-1381 
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expanding multi-layered stent constructed of cobalt alloy wires interconnected in five layers. Thereby, blood flow 1382 
through the stent is laminated reducing turbulence in the aneurysmal sac leading to sac thrombosis. Conflicting 1383 
evidence regarding the mechanisms and efficacy currently remain unsolved (220–224) 1384 
  1385 
RECOMMENDATION 33 The parallel graft technique should be considered in urgent TEVAR procedures 1386 
requiring seal in landing zones 0-2 without adequate options for open surgery or supraaortic debranching and as 1387 
a bail out strategy in cases where unintended obstruction of a supra aortic vessel occurred during TEVAR. Class 1388 
IIA Level C   1389 
 1390 
RECOMMENDATION 34 The parallel graft technique is not recommended as a routine strategy in preserving flow 1391 
to major supraaortic branches in Zone 0-2 if other strategies (open surgery, branched/fenestrated stent-grafts) are 1392 
available. Class III Level C     1393 
 1394 
RECOMMENDATION 35 The Multilayer technique is not recommended for the treatment of any kind of aortic 1395 
arch pathology. Class III Level C     1396 
 1397 
1398 
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 1399 
11) Ten bullet points when to choose what kind of approach  1400 
 1401 
 1402 
 1403 
V favors 1404 
X discourages1405 
Factors favoring one or the other approach Endovascular repair Open repair 
Previous CABG with patent IMA graft at risk at 
resternotomy 
V X 
Poor LV- or RV-function V X 
Poor pulmonary function V X 
Poor liver function V X 
Connective tissue disorder patients with landing zones 
in native tissue 
X V 
Access vessels (femoral and iliac) diameter < 7mm X V 
Native ascending aorta diameter  > 38mm X V 
Valvular heart disease necessitating concomitant repair X V 
Previous mechanical aortic valve replacement X V 
Prosthetic ascending aorta short or kinked  X V 
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 1406 
12)  Rare pathologies  1407 
 1408 
a) Thrombus 1409 
Aortic thrombus is a rare entity (225). The aortic arch and the DTA have been recognized as predilection sites for 1410 
aortic thrombus (226). Aortic arch thrombus bears the risk of life-threatening stroke and peripheral embolization 1411 
(227). The thrombus morphology should be taken into consideration distinguishing mobile (i.e. floating, bulging 1412 
into the lumen) from stationary (mural lining) thrombus. Symptomatic patients (i.e. ischaemia due to embolization: 1413 
stroke, limb ischaemia, visceral or renal ischaemia) often require urgent treatment and in asymptomatic patients 1414 
the diagnosis is mostly a chance finding in imaging studies performed for other reasons. There is a high 1415 
prevalence of hypercoagulation and hematologic disorders including malignancy in patients with aortic thrombus 1416 
(226). This has to be considered when establishing individual treatment strategies. Other possible sources of 1417 
embolization have to be ruled out preoperatively in symptomatic patients. Treatment options include conservative 1418 
management (anticoagulation) and surgery (thrombectomy, local resection of attachment site, aortic arch 1419 
replacement or debranching and thoracic endovascular repair). However, endovascular treatment requires an 1420 
adequate landing zone in the ascending and DTA. Furthermore, guidewire and stent-graft manipulation in the 1421 
thrombotic aortic arch bear an additional risk for embolization. A hybrid approach with supra-aortic debranching 1422 
and antegrade stent-graft implantation has been reported (228). A recently published case series reported 1423 
excellent outcome with regard to survival and freedom from recurrence of thrombus formation with surgical 1424 
thrombectomy (227). The value of minimally invasive approaches including trans-arterial balloon thrombectomy or 1425 
catheter based percutaneous thrombus aspiration remains unclear. Follow-up imaging is rcommended in patients 1426 
under conservative treatment to assess for thrombus dissolution. 1427 
 1428 
RECOMMENDATION 36 Surgical treatment should be considered in symptomatic patients with floating aortic 1429 
arch thrombus (IIA C) 1430 
 1431 
RECOMMENDATION 37 Surgical treatment may be considered in symptomatic patients with extensive stationary 1432 
(mural lining) aortic arch thrombus (IIB C) 1433 
 1434 
 1435 
 1436 
 1437 
 1438 
 1439 
 1440 
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b) Aberrant subclavian artery and Kommerell’s diverticulum 1441 
The prevalence of aberrant subclavian artery and Kommerell’s diverticulum is 0.4-2.3 % (229). Anatomically, the 1442 
aberrant subclavian artery passes in 80 % posterior to the oesophagus, in 15 % between the oesophagus and the 1443 
trachea, and in 5 % anterior to the trachea (229). Symptomatic patients suffering from dysphagia, dyspnoea, 1444 
coughing, chest pain, aspiration, or recurrent pulmonary infection represent only 5 %. Asymptomatic patients can 1445 
be managed conservatively. Aneurysmatic aberrant subclavian arteries ≥3 cm in diameter and Kommerell’s 1446 
diverticula with a diameter ≥5.5 should be considered for repair due to their risk of rupture and dissection. But, 1447 
actual size measurement of the Kommerell’s diverticulum is highly controversial with no clear consensus. Tanaka 1448 
et al. recommend to measure Kommerell’s diverticulum from the wall next to the trachea to the opposite aortic 1449 
wall or from the tip of the diverticulum to the opposite aortic wall. Additionally, they measure the subclavian artery 1450 
diameter at its orifice (230). Operative treatment modalities include resection and ligation of the symptomatic or 1451 
aneurysmatic aberrant subclavian artery to release compression (important in symptomatic patients) and 1452 
subclavian-carotid transposition or bypass to re-establish arterial circulation to the right arm. Resection of the 1453 
offspring of the aberrant subclavian artery is not necessary in asymptomatic patients. Kommerell’s diverticulum 1454 
can be treated by stent-graft implantation or DTA replacement. TEVAR might be challenging due to steep arches; 1455 
often present in these patients. 1456 
 1457 
RECOMMENDATION 38 An aneurysmatic subclavian artery (≥3 cm) and/or Kommerell’s diverticulum (≥5.5 cm) 1458 
should be considered for repair. Class IIA Level C     1459 
 1460 
RECOMMENDATION 39 Treatment should be performed in symptomatic patients with aberrant subclavian artery 1461 
and Kommerell’s diverticulum. Class I Level C     1462 
 1463 
 1464 
c) Trauma 1465 
Aortic injury is highly lethal representing the second most common cause of death in blunt trauma after brain 1466 
injury. A lesion at the aortic isthmus in loco typico is present in up to 90% of deceleration trauma patients admitted 1467 
to hospital alive. An autopsy study of 242 fatal blunt aortic injuries showed that isthmus lesions represented 58 % 1468 
and aortic arch lesions were rare (3 %) (231). Iatrogenic lesions associated with catheter manipulation in the arch 1469 
is another possible source of trauma. Timing of repair conforms to the extent of the lesion. Classification of 1470 
traumatic aortic injury according to Azizzadeh et al includes four grades of lesions: I intimal flap, II intramural 1471 
haematoma, III pseudoaneurysm, and IV rupture (232). Whereas grade I and II lesions permit conservative 1472 
management with serial imaging controls, grades III-IV should be repaired. Operative treatment modalities include 1473 
a hybrid approach with supra-aortic debranching and stent-graft implantation or aortic arch replacement. 1474 
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Endovascular management is preferred when feasible. Timing, type and extent of treatment also strongly depend 1475 
on concomitant injuries (e.g. traumatic brain injury). 1476 
 1477 
d) Infection 1478 
Infection of the native aorta or, more often, of an aortic graft encompasses considerable morbidity and mortality. 1479 
For diagnostic purposes a positron emission tomography (PET) scan may add value  to differentiate general 1480 
inflammation (e.g. postoperatively) from infection.  However, metabolic activity on PET-CT is only a minor 1481 
criterium. The MAGIC (Management of Aortic Graft Infection Collaboration)  criteria offer support in the diagnosis 1482 
of aortic graft infection (233). Summarizing, the diagnosis of native aortic or prosthetic aortic infection includes 1483 
clinical/ surgical, radiological, and laboratory data (233). 1484 
 1485 
 Operative treatment modalities include removal of the infected material, local debridement and in-situ aortic 1486 
reconstruction. Conservative treatment may be considered in selected cases (234). TEVAR as emergency 1487 
therapy despite suspected aortic infection is feasible and may well serve as a definite treatment option in selected 1488 
cases (235).  1489 
 1490 
Specific antibiotic and antimycotic treatment according to microbiological analyses has to be established for all 1491 
patients. The appropriate type of material for aortic reconstruction is under discussion: prosthetic (plain, antibiotics 1492 
or silver coated) or biologic (homograft, autologous veins, xenopericardial material) grafts are available. The 1493 
required treatment urgency has an influence on preoperative diagnostic features (imaging and microbiological 1494 
sampling) and the availability of the specific replacement material. Xenopericardial material (self-made tube 1495 
grafts) due to permanent off the shelf availability, ease of handling, and good clinical results is favoured 1496 
(236,237). In addition, antibiotic therapy may be withdrawn in many cases during follow-up which is the exception 1497 
in patients after alloplastic replacement.  1498 
 1499 
RECOMMENDATION 40 Removal of the infected vessel or prosthetic material, local debridement and in-situ 1500 
aortic reconstruction using biological material should be considered in infections of the native aortic arch or aortic 1501 
arch graft. Class IIA Level C     1502 
 1503 
RECOMMENDATION 41 Endovascular repair may be considered for bridging purposes or definite treatment in 1504 
inoperable patients in infections of the native aortic arch or aortic arch graft concomitant to antiinfectious 1505 
therapy. Class IIB Level C   1506 
1507 
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 Aortitis of the aortic arch  1508 
 1509 
Immune-mediated vasculitis represents a frequent and possibly organ- or life-threatening disease in 1510 
rheumatology’s every day practice,   1511 
 1512 
Large vessel vasculitis is the most frequent cause of vasculitis encountered mostly in either young females known 1513 
as Takayasu’s arteritis (TAK) or in people over the age of 50 years known as giant cell arteritis (GCA) (238). Both 1514 
entities share a possible affection of the aortic arch with mostly late detection, the risk of ongoing inflammation 1515 
leading to stenosis and dilatation, finally encountering the risk of aortic rupture.  1516 
 1517 
Giant cell arteritis  1518 
GCA might present with a sudden onset of temporal headache, malaise with signs of a systemic inflammatory 1519 
response syndrome (SIRS) of unknown origin, weakness of shoulder and hip girdle and weight loss. Formerly 1520 
known as Horton’s disease and representing a segmental vasculitic affection of the temporal arteries novel 1521 
diagnostic methods allowed to broaden our understanding of the disease. Meanwhile, CTA as well as MRA and / 1522 
or PET-CT are able to detect additional vasculitic affections of the aorta that are mainly located in the region of 1523 
the aortic arch, DTA and in part abdominal aortic or iliac sections. 1524 
 1525 
Diagnostic approach 1526 
Further diagnostic evaluation of possible aortic affections is reasonable in order not to miss concomitant large 1527 
vessel vasculitis (239). Glucocorticoid (GC) treatment should be withheld until after the procedure if medically 1528 
justifiable: 3 to 5 days after start of GC treatment vessel wall signals mostly disappear resulting in negative results 1529 
despite underlying inflammation (239,240). 1530 
 1531 
Therapy  1532 
In case of temporal arteritis immediate initiation of therapy is warranted in fear of further vasculitic affection of the 1533 
vasculature supplying the optical nerve with a possibly rapid onset of mostly irreversible blindness.  In case of 1534 
additional or isolated large vessel vasculitis rapid reduction of vessel wall inflammation is supposed to reduce 1535 
further sequelae. GCs hereby still represent the mainstay of therapy. Current investigations demonstrated IL 1536 
(Interleukin)-6 as being mainly involved in orchestrating  disease onset as well as the course of disease: 1537 
meanwhile, therapeutic strategies targeting IL-6 and its specific receptor  have proven beneficial in inducing and 1538 
maintaining remission (241,242).  1539 
 1540 
 1541 
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 1542 
Complications and outlook 1543 
Rupture of the aorta and/or its associated branches appears to represent a rare complication yet true incidences 1544 
are difficult to depict as e.g. “silent” GCA will not routinely be followed clinically and/or radiographically. 1545 
Furthermore, the former routine for histological evaluation of the resected vasculature in order to prove 1546 
immunologically driven inflammation has unfortunately lost importance. Follow-up of patients focusses on clinical 1547 
and serological signs of relapse and/or remission. For the time being radiographic diagnostics are not reliable for 1548 
determining ongoing or recurrent vascular inflammation: despite clinical and serological remission persistent MRA 1549 
signals within the vessel wall might represent either persistent low disease activity or formation of new 1550 
vasculature or even display some kind of vascular repair. Nevertheless, MRA and/or PET-CT might prove useful 1551 
in the early detection of vascular damage and should therefore be performed repeatedly.  1552 
 1553 
Takayasu’s arteritis 1554 
TAK manifestations are rarely suspicious of an underlying immune-mediated vascular process but rather point to 1555 
vascular damage after the development of stenosis. As mostly supra-aortic branches of the aortic arch are 1556 
affected patients often present with pulselessness of upper extremities, arm claudication, dizziness or suspicion of 1557 
cerebral ischemia.  1558 
 1559 
Diagnostic approach 1560 
The diagnostic procedure comprises the same imaging methods as in GCA with US being relevant for supraaortic 1561 
branches, and CTA, MRA and PET-CT being reserved for screening of remaining aortic involvements. Active 1562 
lesions are more probably being detected in phases of serological inflammation.  1563 
 1564 
Therapeutic approach 1565 
As in GCA, initial therapy comprises the use of GCs aiming at induction of remission. Therapeutic strategies for 1566 
maintenance of remission are not well characterized within this rare disease. Unspecific immunosuppression 1567 
targeting the involved lymphocytic subgroups by using e.g. azathioprine or methotrexate have empirically proven 1568 
beneficial. Therapeutic strategies aiming at TNF (Tumor necrosis factor)-alpha and anti IL-6 yield positive results 1569 
and suggest further adaptations for future therapies (243,244).  1570 
 1571 
Complications 1572 
Vascular reconstruction might be demanded indicated in the late phase of the disease when symptomatic 1573 
stenoses occur leading to reduced perfusion in the connected arterial segment. Vascular interventions as e.g. 1574 
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dilatations appear of only little benefit due to the inflammatory nature of the disease with prompt re-stenoses 1575 
occurring quite frequently. Stenting and/or vascular repair have proven more beneficial.  1576 
Conclusion 1577 
Overall, suspicion of large vessel vasculitis due to autoimmune pathophysiology should be considered in either 1578 
young females presenting with mostly late complications of upper extremity claudication and supraaortic 1579 
malperfusion (TAK) and in people over the age of  older than 50 years with sudden onset of an inflammatory 1580 
syndrome of unknown origin, temporal headache and constitutional symptoms (GCA). Prompt diagnosis and 1581 
therapy especially in GCA will help to minimize the initial risk of permanent loss of vision and to reduce the 1582 
occurrence of long term vascular complications.  1583 
 1584 
 1585 
1586 
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 1587 
13) Durability and reporting standards/ quality indicators 1588 
 1589 
While reporting standards in classical adult cardiac or vascular surgery have widely been established, there is 1590 
work to do in the aortic sector in particular when it comes to treatment of the aortic arch. As long as no 1591 
preoperative risk stratification score for aortic disease has been established, currently available risk score 1592 
systems like STS-PROM (67) or ES I and II (68) may help in predicting risk with their known limitations when 1593 
applied to patients with aortic disease. However, the main advantage when using them in their current form is the 1594 
potential comparability between studies where currently there is no least common denominator available. 1595 
 1596 
The results of endovascular repair should be reported according to current SVS (Society of Vascular Surgery) 1597 
guidelines that consider both technical and clinical endpoints in order to evaluate the performance of the devices 1598 
combined to the clinical outcomes of their application. Clinical outcomes for aortic arch treatment should clearly 1599 
include 30 day mortality as well as neurological outcomes (stroke and spinal cord ischemia). Moreover, the 1600 
completeness of follow-up information is of paramount importance and cannot be overemphasized (245). 1601 
Neurological outcomes should be reported according to current recommendations (246).Currently, there is no 1602 
robust evidence to recommend minimum case-loads for aortic arch procedures both open and endo neither for 1603 
centers nor for individual physicians but a clear volume-outcome correlation like in many other cardiovascular 1604 
procedures supports centralization and specialization (16,87,247). 1605 
 1606 
 1607 
1608 
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 1609 
14) Gaps in Evidence  1610 
 1611 
Supportive evidence level in above recommendations for the management of aortic arch diseases is mostly “C”, 1612 
for several reasons. The patient population requiring aortic arch procedures is small compared to other 1613 
cardiovascular patient populations, although growing. Caseload is low in many centers, and published series tend 1614 
to be small in numbers. Also, there is much heterogeneity in presentations, patients, and treatment approaches. 1615 
In particular, therapies in the area of aortic arch pathologies are driven by rapid innovations in technology as well 1616 
as by institutional preference. Therefore it is very clear that close international scientific and clinical collaboration 1617 
will be required to solve these issues. 1618 
 1619 
 1620 
The following unmet needs and gaps in evidence are identified, as a topic of future clinical research in the field: 1621 
An increase of evidence in the pathophysiology and in the prevention of perioperative stroke 1622 
- An increase of evidence in selecting the best treatment option in patients with acute and chronic 1623 
aortic arch disease 1624 
- A need for further international standardization of terminology 1625 
- A need for standardized surveillance and for follow-up after treatment   1626 
- A need to develop prospectively maintained, large multicentric clinical databases for aortic arch 1627 
pathologies. 1628 
This is in recognition of the shortcomings of current Cardiovascular Surgical Risk Scoring Systems in this 1629 
field (248).  As an initiative, the  STS Task Force on Aortic Surgery has already developed new sections 1630 
pertaining to aortic root and thoracic aortic surgery to reflect technical advances in open and 1631 
endovascular aortic procedures (69). An exemplary set of pertinent variables is given in the STS Aorta 1632 
Surgery Worksheet V2.9 (249). 1633 
- Data-driven development and continuous adaptation of dedicated CPM for Aortic Arch Repair 1634 
- Accrual of more evidence on effects of caseload and centralization of care on outcome of aortic arch 1635 
repair 1636 
- A need to address frailty (250–252) and gender differences in outcome research 1637 
- A need to define differences in the risk of acute dissection among genetically mediated aortic disease 1638 
syndromes  1639 
- In type A dissection, to better define the extent of index surgery 1640 
- Improving the evidence for measures to reduce lower body circulatory arrest time and for selective 1641 
myocardial perfusion during open aortic arch repair 1642 
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- To resolve the controversy upon the use of stent-grafts in connective tissue disease 1643 
 1644 
 1645 
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